

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/40, 7/01, 7/04, 15/86, A61K 39/193</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/53077</b> <b>(43) International Publication Date:</b> 26 November 1998 (26.11.98)
<b>(21) International Application Number:</b> PCT/US98/10645 <b>(22) International Filing Date:</b> 20 May 1998 (20.05.98)  <b>(30) Priority Data:</b> 60/047,162 20 May 1997 (20.05.97) US 60/053,652 24 July 1997 (24.07.97) US 08/991,840 16 December 1997 (16.12.97) US  <b>(71) Applicant (for all designated States except US):</b> WALTER REED ARMY INSTITUTE OF RESEARCH [-/US]; Dept. of the Army, Washington, DC 20307 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> PARKER, Michael, D. [US/US]; Apartment T-13, 1001 Carroll Parkway, Frederick, MD 21701 (US). SMITH, Jonathan, F. [US/US]; 6936 Eyler Valley Flint Road, Sabillasville, MD 21780 (US). CRISE, Bruce, J. [US/US]; 7210 McKaig Road, Frederick, MD 21701 (US). OBERSTE, Mark, Steve [US/US]; 5110 Sunset Maple Trace, Lilburn, GA 30247 (US). SCHMURA, Shannon, M. [US/US]; 10812 Lincoln Avenue, Hagerstown, MD 21740 (US).			<b>(74) Agent:</b> HARRIS, Charles, H.; United States Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702 (US).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> LIVE ATTENUATED VIRUS VACCINES FOR EQUINE ENCEPHALITIS VIRUSES			
<b>(57) Abstract</b>  cDNAs coding for an infectious Western Equine Encephalitis virus (WEE) and infectious Venezuelan Equine Encephalitis virus variant IE (VEE IE) are disclosed in addition to cDNA coding for the structural proteins of Venezuelan Equine Encephalitis virus variant IIIA (VEE IIIA). Novel attenuating mutations of WEE and VEE IE and their uses are described. Also disclosed are attenuated chimeric alphaviruses and their uses.			
<b>BEST AVAILABLE COPY</b>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## TITLE OF THE INVENTION

LIVE ATTENUATED VIRUS VACCINES FOR EQUINE ENCEPHALITIS VIRUSES

5

10

## INTRODUCTION

Western equine encephalitis (WEE), eastern equine  
15 encephalitis (EEE) and Venezuelan equine encephalitis  
virus (VEE) are members of the alphavirus genus of the  
family Togaviridae which is comprised of a large group  
of mosquito-borne RNA viruses found throughout much of  
the world. The viruses normally circulate among  
20 rodent or avian hosts through the feeding activities  
of a variety of mosquitoes. Epizootics occur largely  
as a result of increased mosquito activity after  
periods of increased rainfall. Western equine  
encephalitis virus (WEE) was first recognized in 1930  
25 and causes periodic outbreaks of disease in equines.  
The virus has been detected over much of the western  
hemisphere from Argentina north to the more temperate  
regions of central Canada (For a review, see Reisen  
and Monath [1988] in The Arboviruses: Epidemiology and  
30 Ecology, Vol. V. CRC Press, Inc. Boca Raton).  
Similarly, EEE was first isolated in Virginia and New  
Jersey in 1933 (Ten Broeck, C. et al. [1935] *J. Exp.*  
*Med.* **62**:677) and is now known to be focally endemic  
throughout much of the northern portion of South

America, Central America and the eastern part of Mexico and the United States. Venezuelan equine encephalitis virus has six serological subtypes (I-VI). Two of these subtypes, I and III have multiple variants, two of these variants are of particular interest in this application, variant IE, and variant IIIA also called Mucambo virus. A live, attenuated vaccine (TC-83) for VEE IA/B has been used for immunization equines and at-risk laboratory and field personnel (Birge et al. [1961] *Am. J. Hyg.* **73**:209-218; Pittman et al. [1996] *Vaccine* **14**:337-343). The vaccine was credited with helping to limit the northward spread of a serious epizootic of VEE originating in South America in the late 1960's. However, the VEE I/AB vaccines have not yet been licensed by the Food and Drug Administration and have been shown to be effective in preventing disease from VEE IA/B infection only. The current VEE vaccines do not adequately protect against the VEE IE variant or the VEE IIIA variant, as disease has occurred in laboratory workers successfully vaccinated with a vaccine derived from VEE IA/B. In addition, recent unprecedented outbreaks of VEE IE in populations of horses in Mexico indicate a need for a VEE IE vaccine. The lack of adequate cross protection with existing IA/B vaccines documents the need for a VEE IE-specific and a VEE IIIA-specific vaccine.

The vaccines currently in veterinary use for WEE, EEE and VEE IA/B throughout the United States and Canada are formalin-inactivated preparations. Inactivated vaccines for EEE and WEE are also available for use by at-risk laboratory personnel. These inactivated vaccines are poorly immunogenic, require multiple inoculations with frequent boosters and generally result in immunity of short duration.

The shortcomings of the available vaccines indicate a need for the development of new vaccines of high immunogenicity which induce a longer lasting immunity for protection against WEE, EEE and VEE subtypes IE and IIIA.

### SUMMARY OF THE INVENTION

The present invention satisfies the need mentioned above.

10 In this application are described live attenuated vaccines for WEE, EEE, VEE IE and VEE IIIA which may provide higher level immunity in humans and equines for many years, and possibly for life. In addition, very large numbers of vaccine doses can be produced  
15 from significantly less starting materials than is possible with the existing inactivated products. The vaccine preparations of the present invention comprise full-length cDNA copies of the genomes of WEE or VEE IE which have been altered such that the RNA produced  
20 from the cDNA, and the virus produced therefrom is attenuated and useful as a live vaccine for human and veterinary use. The vaccine preparations for VEE IIIA and EEE are novel chimeric viruses which include the newly discovered structural protein genes of VEE IIIA.

25 The classic methods of deriving live-attenuated vaccines (blind passage in cell cultures) generally result in heterogeneous and undefined products, hence recent attempts to make live vaccines for alphaviruses have relied on genetic engineering procedures.

30 The alphavirus genome is a single-stranded, positive-stranded RNA approximately 11,400 nucleotides in length. The 5' two-thirds of the genome consist of a non-coding region of approximately 48 nucleotides followed by a single open reading frame of  
35 approximately 7,500 nucleotides which encodes the

viral replicase/transcriptase. The 3' one-third of the genome encodes the viral structural proteins in the order C-E3-E2-6K-E1, each of which are derived by proteolytic cleavage of the product of a single open reading frame of approximately 3700 nucleotides. The sequences encoding the structural proteins are transcribed as a 26S mRNA from an internal promoter on the negative sense complement of the viral genome. The nucleocapsid (C) protein possesses autoproteolytic activity which cleaves the C protein from the precursor protein soon after the ribosome transits the junction between the C and E3 protein coding sequence. Subsequently, the envelope glycoproteins E2 and E1 are derived by proteolytic cleavage in association with intracellular membranes and form heterodimers. E2 initially appears in the infected cell as a precursor, pE2, which consists of E3 and E2. After extensive glycosylation and transit through the endoplasmic reticulum and the golgi apparatus, E3 is cleaved from E2 by furin-like protease activity at a cleavage site having a consensus sequence of RX(K/R)R, with X being one of many amino acids present in the different viruses, and with the cleavage occurring after the last arginine residue. Subsequently, the E2/E1 complex is transported to the cell surface where it is incorporated into virus budding from the plasma membrane (Strauss and Strauss [1994] *Microbiological Rev.* 58: 491-562). All documents cited herein *supra* and *infra* are hereby incorporated in their entirety by reference thereto.

Because the genome of alphavirus is a positive-stranded RNA, and infectious upon transfection of cells in culture, an "infectious clone" approach to vaccine development is particularly suitable for the alphaviruses. In this approach, a full-length cDNA

clone of the viral genome is constructed downstream from a RNA polymerase promoter, such that RNA which is equivalent to the viral genome can be transcribed from the DNA clone *in vitro*. This allows site-directed  
5 mutagenesis procedures to be used to insert specific mutations into the DNA clone, which are then reflected in the virus which is recovered by transfection of the RNA.

Previous work with infectious clones of other  
10 alphaviruses has demonstrated that disruption of the furin cleavage site results in a virus which incorporates pE2 into the mature virus. Davis *et al.* (1995, *supra*) found that disruption of the furin cleavage site in an infectious clone of VEE is a  
15 lethal mutation. Transfection of BHK cells with RNA transcribed from this mutant clone resulted in the release of non-infectious particles. However, a low level of infectious virus was produced which contained secondary suppressor mutations such that virus  
20 containing pE2 was fully replication competent and subsequently shown to be avirulent but capable of eliciting immunity to lethal virus challenge in a variety of animal species.

The genetic basis for attenuation of the VEE TC-  
25 83 vaccine and certain laboratory strains of VEE virus have been studied extensively and has led to the development of improved live, attenuated vaccine candidates (Kinney *et al.* 1993, *supra*, Davis *et al.* 1995, *supra*). The approach used in this application  
30 is similar to that used for VEE, however, following the VEE example exactly did not result in an adequate vaccine for WEE. Changes in the procedure used for VEE were required, none of which could have been predicted from the VEE work, in order to produce the  
35 attenuated live WEE virus of the present invention.

Based upon a comparison of the structural protein gene sequences of WEE and other alphaviruses, the probable furin cleavage site of WEE strain CBA/87 virus is RRPKR. The presence of the extra arginine when compared to the consensus (RX(R/K)R) alphavirus cleavage site indicated that the cleavage at this site might be more complex than that observed with VEE virus. It was necessary therefore to prepare two deletion mutations in the E3-E2 cleavage site of the full-length clone, one which lacks five amino acids and one which lacks four amino acids since it was unknown which mutation, if any, would produce an attenuated virus. The residual arginine in the full-length clone lacking only four amino acids was of concern due to the possibility that other mutations might arise due to the presence of the extra arginine resulting in cleavage by cellular proteases at that site and producing an apparently wild type virus with respect to cleavage of pE2.

Transfection of cultured cells with RNA transcribed from an infectious clone of WEE lacking the furin cleavage site yielded viruses which contained the pE2 of WEE in the mature virus but which were not replication competent. During intracellular replication of the RNA, mutations arise at low frequency, resulting in a small number of replication competent virus. Sequence analysis of these viruses has shown that the lethal effect of the deletion mutations was alleviated by the appearance of second site mutations in the E2 glycoprotein. These viruses are attenuated in mice when administered by subcutaneous or intracranial inoculation. The mice produce high titer neutralizing and ELISA antibody and are protected against a lethal challenge of parental virulent WEE virus.



Therefore, in one aspect of the invention, the invention pertains to the isolation of a cDNA sequence coding for an infectious western equine encephalitis (WEE) virus RNA transcript. DNA representing the entire genome, not previously available, was prepared by polymerase chain reaction using a series of primer pairs based upon the partial genome sequences previously deposited in Genbank. The 5' and 3' ends of the viral genome were unknown and difficult to obtain. The terminal sequence was necessary for efficient replication of the virus since substitution of ends from a similar virus with similar but not identical sequences resulted in an extremely attenuated virus. In order to determine the correct sequence at the 5' end, a protocol called rapid amplification of cDNA ends (5'-RACE) was used. The full length infectious clone is useful in the production of virulent WEE virus, and introducing and testing attenuating mutations. The production of virulent virus is essential for a formal measure of the degree of attenuation achieved with candidate attenuating mutations and a formal determination of the rate at which reversion to virulence might occur.

In another aspect of the invention, the invention pertains to the isolation of a cDNA sequence coding for an infectious Venezuelan equine encephalitis virus IE variant (VEE IE) virus RNA transcript (SEQ ID NO: 2). Using oligonucleotides specific to genomic RNA of a VEE IE isolate (GenBank accession no. U34999) (Oberste, et al. [1996] *Virology* **219**:314-320), reverse transcriptase polymerase chain reaction was carried out to generate numerous cDNA fragments which were subsequently cloned and used to assemble full-length cDNA of VEE IE. The full length infectious clone is useful, for example, in the production of

virulent VEE IE virus, and introducing and testing attenuating mutations.

In the case of VEE IIIA, the structural protein genes were removed from a full length clone of VEE IA/B and replaced by the VEE IIIA structural genes. The IIIA structural gene sequences were prepared by RT-PCR and include the IIIA 26S promoter and the 3' nontranslated region (3'NTR) flanking the sequences for the structural proteins (SEQ ID NO:3). The VEE IIIA 3' NTR was then replaced with the VEE IA/B NTR, and the modified sequence was cloned back into the VEE IA/B full length clone. The result was a clone in which the nonstructural protein gene sequences were from VEE IA/B and the structural protein gene sequences from VEE IIIA. The virus produced from this chimeric clone replicated efficiently in cell culture, and proved to be completely attenuated in mice. In addition, it was highly immunogenic and protected the vaccinated mice against challenge with virulent, wild-type Mucambo virus (VEE IIIA).

Portions of the cDNA sequences described above are useful as probes to diagnose the presence of virus in samples, and to define naturally occurring variants of the virus. These cDNAs also make available polypeptide sequences of WEE antigens, EEE antigens, VEE IE antigens, and VEE IIIA structural polypeptide antigens encoded within the respective genomes and permits the production of polypeptides which are useful as standards or reagents in diagnostic tests and/or as components of vaccines. Antibodies, both polyclonal and monoclonal, directed against WEE epitopes, EEE epitopes, VEE IE epitopes, or VEE IIIA epitopes contained within these polypeptide sequences are also useful for diagnostic tests, as therapeutic agents, and for screening of antiviral agents.

Accordingly, with respect to polynucleotides, some aspects of the invention are: a purified WEE polynucleotide; a recombinant WEE polynucleotide; a recombinant polynucleotide comprising a sequence  
5 derived from a WEE genome or from WEE cDNA; a recombinant polynucleotide encoding an epitope of WEE; a recombinant vector containing any of the above recombinant polynucleotides, and a host cell transfected with any of these vectors.

10 Other aspects of the invention are: a purified VEE IE polynucleotide; a recombinant VEE IE polynucleotide; a recombinant polynucleotide comprising a sequence derived from a VEE IE genome or from VEE IE cDNA; a recombinant polynucleotide  
15 encoding an epitope of VEE IE; a recombinant vector containing any of the above recombinant polynucleotides, and a host cell transformed with any of these vectors.

In a further aspect of the invention is a  
20 complete sequence of the VEE subtype IIIA structural protein genes useful for diagnostics and vaccine development. Also provided is a chimeric virus containing the structural sequences of VEE IIIA, which is completely attenuated and provides protection  
25 against challenge with VEE IIIA virulent virus for use as a vaccine

Another aspect of the invention is a single-stranded DNA sequence comprising a cDNA clone coding for an infectious WEE, the cDNA clone including at  
30 least one attenuating mutation therein, the RNA produced from transcription of the cDNA and the virus particles produced from the RNA in a host cell for use as a vaccine.

In another aspect of the invention there is  
35 provided a full length WEE cDNA clone containing a

defined deletion mutation useful for attenuating the virus for the identification of suppressor mutations in the virus. The attenuated virus with the cleavage deletion and suppressor mutations are useful as a means to generate an attenuated, live WEE virus vaccine for veterinary and human use.

In a further aspect of the invention is provided a chimeric virus containing nonstructural protein gene sequences from WEE and structural protein gene sequences from any alphaviruses including but not limited to Aura, Barmah Forest, Bebaru, Cabassou, Chikungunya, eastern equine encephalitis, Everglades, Fort Morgan, Getah, Highlands J, Kyzylagach, Mayaro, Middelburg, Mucambo, Ndumu, O'nyong-nyong, Pixuna, Ross River, Sagiya, Semliki Forest, SAAR87, Sindbis, Tonate, Una, Venezuelan equine encephalitis, Whataroa, which could be used as a means for attenuating virulent alphaviruses, and vaccine production against other alphaviruses.

Taking advantage of the close evolutionary relationship between WEE and eastern equine encephalitis virus (EEE), a chimeric virus has been constructed in which the structural protein genes of EEE have been inserted into the infectious clone in place of the WEE structural protein genes. The resulting virus is fully replication competent, attenuated, and elicits an immune response in mice which is protective against a lethal challenge with virulent EEE virus.

In addition, depending on the non-WEE sequences substituted for the WEE structural genes, another aspect of the invention includes a means for expressing antigens of other alphaviruses as chimeric alphaviruses for use as potential vaccines for human and veterinary use.

In another aspect of the invention there is provided a full length infectious VEE IE cDNA clone containing a cleavage deletion useful in the identification of suppressor mutations in the virus, the RNA produced from the cDNA and the virus produced from the RNA. The virus with the cleavage deletion and suppressor mutations is useful as a means to generate an attenuated, live VEE IE vaccine virus for veterinary and human use.

10 In a further aspect of the invention is provided a chimeric virus containing nonstructural sequences from VEE IE and structural sequences from other alphaviruses which could be used as a means of attenuating virulent alphaviruses.

15 In addition, depending on the non-VEE IE sequences substituted for the structural sequences of VEE IE, another aspect of the invention includes a means to express antigens of other alphaviruses as chimeric alphaviruses as potential vaccines for human and veterinary use.

20 In a further aspect of the invention, there is provided a vaccine protective against WEE, the vaccine comprising live attenuated WEE virus in an amount effective to elicit protective antibodies in an animal to WEE and a pharmaceutically acceptable diluent, carrier, or excipient.

25 In yet a further aspect of the invention, there is provided a vaccine protective against VEE IE, the vaccine comprising live attenuated VEE IE virus in an amount effective to elicit protective antibodies in an animal to VEE IE and a pharmaceutically acceptable diluent, carrier, or excipient.

30 In another aspect of the invention, there is provided a bivalent vaccine protective against WEE and VEE IE, the vaccine comprising both attenuated WEE and

attenuated VEE IE in an amount effective to elicit protective antibodies in an animal to both WEE and VEE IE and a pharmaceutically acceptable diluent. In addition, it is possible that this vaccine will  
5 provide short lived protection against other alphaviruses (Cole and McKinney [1971] *Inf. Immunity* 4:37-43).

In yet another aspect of the invention, there is provided an inactivated vaccine produced from the live  
10 attenuated virus described above. The attenuated virus of the present invention whether whole virus or chimeric virus can be used in producing inactivated virus vaccines. By using an attenuated virus strain, there is a much greater margin of safety in the event  
15 that the produce is incompletely inactivated. Starting with an attenuated strain is also much safer during the manufacturing phase, and allows production under lower biocontainment levels.

#### 20 **BRIEF DESCRIPTION OF THE DRAWINGS**

These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and  
25 appended claims, and accompanying drawings where:

**Figure 1A, 1B and 1C.** Assembly of the full length cDNA clone of western equine encephalitis virus. Polymerase chain reaction products representing the entire genome of WEE virus were  
30 prepared with the primer pairs indicated. Each of the products was cloned into pBluescript KS+. Assembly of the full length clone, pWE2000 in pBluescript was carried out as indicated in the figure and described below. The clones are not drawn to scale. In each of  
35 the plasmids, the primers used to generate the PCR

products are indicated as are the restriction endonuclease sites used for the assembly.

**Figure 2.** Polypeptide profiles of western equine encephalitis viruses. Samples of purified virus were analyzed by electrophoresis on 10% polyacrylamide gels and stained with Comassie Brilliant blue. Molecular weight marker (MW) are shown in the first lane and molecular weights are indicated in daltons  $\times 10^{-1}$ . The virus strain is designated above the appropriate lane. Position of contaminating bovine serum albumin is indicated by arrow.

**Figure 3.** Polypeptide profiles of western equine encephalitis virus (WEE), eastern equine encephalitis (EEE) and chimeric virus, MWE. Samples of purified virus were analyzed by electrophoresis on 10% polyacrylamide gels and stained with Comassie Brilliant blue. Molecular weight markers (MW) are shown and molecular weights are indicated in daltons  $\times 10^{-3}$ . Position of contaminating bovine serum albumin is indicated by arrow.

**Figure 4.** Derivation of virulent VEE IE clone. Constructions of cDNA encoding the entire genome of cloned strain 68U201 are shown. The relevant cloning sites and genetic markers are indicated above each clone. The first full-length clone produced that replicated *in vitro* after transfection of the RNA transcribed from the T7 promoter, was pIE-1006. Further modifications to this clone were carried out in order to obtain pIE-1009 that had the *in vitro* and *in vivo* characteristics of the parental, biological isolate, strain 68U201. With a fully virulent clone, pIE-1009 available, specific attenuating mutations

were introduced into pIE-1009 to generate the attenuated clone, pIE1100. Drawings are not to scale. Shaded areas represent regions of pIE1006 that were replaced or mutated to generate new clones.

5

**Figure 5.** Construction of IAB-IIIA cDNA chimeric clone pV3A-1000.

#### DETAILED DESCRIPTION

10 In one embodiment, the present invention relates to a full length cDNA clone of fully virulent WEE virus specified in SEQ ID NO:1, and a full length cDNA clone of fully virulent VEE IE variant specified in SEQ ID NO:2.

15 WEE, strain CBA/87, isolated from the brains of an infected horse in Argentina in 1987 (Bianchi et al., [1987] *Am.J. Trop. Med. Hyg.* **49**:322-328) was used as a parent strain in the instant invention. Any other strain which consistently kills 100% of 5 week old  
20 C57BL6 mice when inoculated subcutaneously can be used such as B11, for example. The cDNA clone can be generated by any of a variety of standard methods known in the art. Preferably, DNA representing the entire genome can be prepared by polymerase chain  
25 reaction using a series of primer pairs based upon the partial genome sequences previously deposited in GenBank. The 5' terminal sequence of the virus may be determined by 5'-RACE basically as described by Frohman et al. ([1988] *Proc. Natl. Acad. Sci. U.S.A.*  
30 **85**:8998-9002). Assembly of the full length clone can be in a suitable transcription vector such as, for example, pBluescript KS+, using convenient restriction endonuclease sites or the entire genome could be inserted into any plasmid which contains suitable  
35 restriction endonuclease cleavage sites for cloning,



an origin of replication so that the plasmid can be propagated in a bacterial host, and a selectable marker gene to maintain the plasmid in the bacterial cell during growth. The DNA sequence preferably has a complementary DNA sequence bonded thereto so that the double-stranded sequence will serve as an active template for RNA polymerase. Hence, the transcription vector preferably comprises a plasmid. When the DNA sequence comprises a plasmid, it is preferred that a unique restriction site be provided 3' (with respect to the virion RNA sequence) to ("down-stream" from) the cDNA clone. This provides a means for linearizing the DNA sequence to enhance the efficiency of transcription of genome-length RNA *in vitro*.

The complete clone is preferably operatively associated with a promoter region such that the promoter causes the cDNA clone to be transcribed in the presence of an RNA polymerase which binds to the promoter. The promoter is positioned on the 5' end (with respect to the virion RNA sequence), or upstream from, the cDNA clone. An excessive number of nucleotides between the promoter sequence and the cDNA clone will result in the inoperability of the construct. Hence, the number of nucleotides between the promoter sequence and the cDNA clone is preferably not more than eight, more preferably not more than than 5, still more preferably not more than 3, and most preferably not more than 1. Exemplary promoters useful in the present invention include, but are not limited to, T3 promoters, T7 promoters, and SP6 promoters. It is preferable that the 5' end of the *in vitro* transcript not have any additional nucleotides preceding the first nucleotide of the viral sequence. At the 3' end, additional nucleotides can be tolerated in the *in vitro* transcript but are probably lost when

the virus replicates. In most instances, the poly-dA tract at the 3' end is required for viability of the virus. Selection of the virulent full length clone can be achieved by comparing the LD<sub>50</sub> of the virus encoded by the cloned cDNA with the LD<sub>50</sub> of the parent virus used, in the instant example, WEE CBA/87. The ability to produce virulent virus is important; it allows the introduction and testing of attenuation mutations and the attenuated phenotype against a standard: the virulent parent.

Transfection of cells with the RNA transcript coded by the full length genomic cDNA can be achieved by any suitable means, such as, for example, by treating the cells with DEAE dextran, treating the cells with "LIPOFECTIN", and by electroporation. Togavirus-permissive cells, alphavirus-permissive cells, and WEE-permissive and VEE IE-permissive cells are cells which, upon transfection with the viral RNA transcript, are capable of producing viral particles. Togaviruses have a broad host range. Examples of such cells include, but are not limited to, Vero cells, baby hamster kidney cells, chicken embryo fibroblast cells, Chinese hamster ovary cells (CHO), mouse L cells, MRC-5 cells, mosquito cells such as C6-36 cells, to name a few.

In the case of VEE IE, an isolate of VEE IE, strain 68U201, was used. Any isolate known to cause disease in man can be chosen. In addition the ability of a strain to have an easily identifiable phenotype such as, for example, the ability to form large plaques in tissue culture on indicator cell monolayers, is helpful. In the present invention, the full length clone of VEE IE was obtained using oligonucleotide primers specific for the VEE IE strain 68U201 sequence. Reverse transcription-polymerase

chain reaction (RT-PCR) of strain 68U201 viral RNA was carried out to generate numerous cDNA fragments that were subsequently cloned and used to assemble a full-length cDNA in a plasmid such that the cDNA could be precisely transcribed and viral infectious RNA produced. It is also possible to produce the entire genome by polymerase chain reaction by including the promoter sequence in the 5' end primer thereby producing infectious RNA directly from the PCR fragment. It is also possible to transcribe the viral RNA from a plasmid in the cell by transfection with the appropriate plasmid containing a promoter utilized by cellular RNA polymerases, i.e. the CMV promoter.

To determine virulence of the cloned viral genome, mice can be inoculated subcutaneously with  $10^4$  plaque forming units of the cloned virus. The clone is considered virulent if all mice die, and not fully virulent if mice do not all die. The  $LD_{50}$  of parent VEE IE strain 68U201 is to 1-2 pfu, therefore, if inoculation of 10,000-fold did not cause lethal disease in all mice, it was considered attenuated.

In another embodiment of the present invention is provided a cDNA sequence of the entire 26S region of VEE subtype IIIA as well as the structural protein genes specified in SEQ ID NO:3.

DNA or polynucleotide sequences to which the invention also relates include sequences of at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, most preferably at least about 15-20 nucleotides corresponding, i.e., homologous to or complementary to, a region of the WEE, VEE IE, or VEE IIIA nucleotide sequence. Preferably, the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is

unique to the virus. Whether or not a sequence is unique to the virus can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., GenBank. Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-translated regions.

The derived polynucleotide is not necessarily physically derived from the nucleotide sequence of the alphaviruses, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use. The sequences of the present invention can be used in diagnostic assays such as hybridization assays and polymerase chain reaction assays and for the discovery of other alphavirus sequences.

A polypeptide or amino acid sequence derived from the amino acid sequence of alphavirus, refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 2-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with as a polypeptide encoded in the sequence.

A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid

sequence, it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system.

Once a complete viral genomic cDNA is cloned,  
5 attenuation of the virus is possible. An attenuating mutation refers to a nucleotide mutation or amino acid coded for in view of such a mutation which results in a decreased probability of causing disease in its host (i.e., a loss of virulence), in accordance with  
10 standard terminology in the art. The attenuating mutation may be a substitution mutation or an in-frame deletion mutation.

Novel WEE attenuating mutations disclosed herein which may be used to carry out the present invention  
15 include deletion of five amino acids at the furin cleavage site in combination with a substitution of lysine for glutamic acid at codon 182 at E2, or deletion of five amino acids at the furin cleavage site in combination with a substitution of lysine for  
20 glutamic acid at codon 181 at E2. Additionally, certain mutations placed in the non-coding region at the 5' end of the genome have been found to be attenuating, specifically, a C to T change at nucleotide 7, an A to G change at nucleotide 13, a T  
25 to A change at nucleotide 25 and deletion of an A at nucleotide 22. These novel attenuating mutations may be inserted together in a cDNA clone encoding WEE virus resulting in an attenuated WEE which is reflected by 100% survival of mice inoculated by  
30 subcutaneous and intracranial routes. Such an attenuated live virus is immunogenic and protective against a lethal virus challenge.

Novel attenuating mutations can be discovered in the VEE IE by introducing mutations which are not  
35 reparable by the viral RNA replication process. A

preferable mutation is the deletion of the four amino acids of the furin-like cleavage site between the E3 and E2 proteins. Transfection of the mutant viral genome into cells can result in the suppression of the lethal effect of the deletion mutation due to the error prone process of alphavirus replication. Once efficiently replicating viral progeny is generated they can be detected by plaque assays and analyzed for the presence of pE2 protein which indicates that the virus contains the deletion mutation. Attenuated but yet immunogenic virus with a cleavage deletion mutation and suppressor mutation(s) could be tested for its ability to protect animals from challenge with virulent VEE IE.

Attenuating mutations may be introduced into cDNAs encoding live WEE or VEE IE by any suitable means, such as site-directed mutagenesis (Please see e.g., Maniatis, Fritsch and Sambrook, Molecular Cloning: A Laboratory Manual (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985) or Current Protocols in Molecular Biology, Ausubel, F. M et al. (Eds.) John Wiley & Sons, Inc., for general cloning methods.).

In another embodiment of the present invention is provided a chimeric virus containing nonstructural sequences from one alphavirus and structural sequences from other alphaviruses which could be used as a means of attenuating virulent alphaviruses. By "Structural sequences" as used herein is meant sequences encoding proteins which are required for encapsidation (e.g., packaging) of the viral genome, and include the capsid protein, E1 glycoprotein, and E2 glycoprotein. By "nonstructural sequences" is meant nonstructural protein sequences, or sequences which encode viral RNA

polymerase(s) proteins. Viruses from which structural sequences can be used in the chimeric virus using WEE "nonstructural genes" as the backbone clone can include for example, all strains of WEE, EEE, and

5 Sindbis, Aura, Barmah Forest, Bebaru, Bijou Bridge, Cabassou, Chikungunya, Everglades, Fort Morgan, Getah, Highlands J, Kyzylagach, Mayaro, Middelburg, Mucambo, Ndumu, O'nyong-nyong, Pixuna, Ross River, Sagiyama, Semliki Forest, SAAR87, Tonate, Una, Venezuelan Equine

10 Encephalitis, Whataroa, to name a few. Acceptable structural protein genes would include a nucleocapsid protein capable of both packaging the chimeric viral genome and which can interact with the glycoproteins to initiate particle assembly. Chimeric virus is

15 constructed by excision of the structural protein genes of the backbone virus and replacement with the desired structural protein genes from another virus. This can be accomplished in one of several ways. For example, site-directed mutagenesis can be used to

20 excise the structural protein genes and leave a restriction endonuclease digestion site at the point of deletion. The structural protein genes of another alphavirus would then be cloned into that restriction site. Any virus obtained after transfection of cells

25 with RNA transcribed from that clone would by definition be a chimeric virus.

In the case where the first and second viruses are closely related, another method can be used wherein cloned structural cDNA sequences of a second

30 alphavirus can be digested at restriction enzyme sites which both viruses have in common. The cDNA fragments of the second virus can then be cloned into the homologous sites in the first virus structural protein locus such that the resulting structural protein genes

35 of the chimeric are a composite of both. Other

methods for producing a chimeric virus are known to people in the art (Kuhn *et al.* [1996] *J. Virology* 70:7900-7909).

5 In another embodiment, the attenuated viruses of the present of invention can be used to prepare replicon expression systems. A replicon expression system consists of three components. The first is a replicon which is equivalent to a full length infectious clone from which all of the viral structural proteins have been deleted. A multiple cloning site can be cloned into the site previously occupied by the structural protein genes. Virtually any heterologous gene may be cloned into this cloning site. Transcription of RNA from the replicon yields 10 an RNA capable of initiating infection of the cell identically to that seen with the full-length infectious virus clone. However, in lieu of the viral structural proteins, the heterologous antigen is expressed. This system does not yield any progeny virus particles because there are no viral structural proteins available to package the RNA into particles. 20

Particles which appear structurally identical to virus particles can be produced by supplying structural proteins for packaging of the replicon RNA in *trans*. This is typically done with two helpers. 25 One helper consists of a full length infectious clone from which the nonstructural protein genes and the glycoprotein genes are deleted. The helper retains only the terminal nucleotide sequences, the promoter for subgenomic mRNA transcription and the sequence for the viral nucleocapsid protein. The second helper is identical to the first except that the nucleocapsid gene is deleted and only the glycoprotein genes are retained. The helper RNA's are transcribed *in vitro* 30 and co-transfected with replicon RNA. Because the 35



replicon RNA retains the sequences for packaging by the nucleocapsid protein, and because the helpers lack these sequences, only the replicon RNA is packaged by the viral structural proteins and released from the cell. The particles can then be inoculated into animals similar to parent virus. The replicon particles will initiate only a single round of replication because the helpers are absent, they produce no progeny virus particles, and express only the viral nonstructural proteins and the product of the heterologous gene cloned in place of the structural proteins. The heterologous gene product is then detected by the host immune system and appropriate immune response is then mounted.

The WEE and VEE IE replicons can be used to express heterologous genes of interest as well as a means for expressing antigens or immunogenic proteins and peptides of interest, *in vitro* or *in vivo*. The immunogenic protein or peptide, or "immunogen" may be any immunogen suitable for inducing an immune response protective against a pathogen from which the immunogen is derived, including but not limited to microbial, bacterial, protozoal, parasitic, and viral pathogens. For example, the immunogen can be the expression product of any heterologous gene of interest, including influenza hemagglutinin, lassa fever nucleocapsid and glycoproteins, portions of bacterial toxin genes, HIV glycoprotein, Ebola glycoprotein, to name a few.

In yet another embodiment, the present invention provides inactivated virus vaccines produced from live attenuated virus preparations, either as virus with attenuating mutations as has been described for WEE and VEE IE or chimeric viruses described above for EEE and VEE IIIA. The inactivation of live virus is well

known in the art and can be performed, for example, by the use of formalin. Inactivated attenuated virus vaccine has a greater safety margin both as a final vaccine in case of incomplete inactivation, and during  
5 the manufacturing process allowing production under lower biocontainment levels.

Subjects which may be administered the live attenuated or inactivated attenuated viruses and vaccine formulations disclosed herein include both  
10 humans and animals (e.g. horse, donkey, pigs, mice, hamster, monkey, birds).

Vaccine formulations of the present invention comprise an immunogenic amount of a live attenuated virus, or a combination of live attenuated viruses as  
15 a multivalent vaccine, as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the attenuated virus sufficient to evoke an immune response, particularly an immune response to the  
20 protein or peptide encoded by the heterologous RNA carried by the virus, in the subject to which the virus is administered. An amount of from about  $10^1$  to  $10^5$  plaque forming units of the live virus per dose is suitable, depending upon the age and species of the  
25 subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.

Administration of the live attenuated viruses  
30 disclosed herein may be carried out by any suitable means, including both parenteral injection (such as intraperitoneal, subcutaneous, or intramuscular injection), by in ovo injection in birds, and by topical application of the virus (typically carried in  
35 the pharmaceutical formulation) to an airway surface.

Topical application of the virus to an airway surface can be carried out by intranasal administration (e.g. by use of dropper, swab, or inhaler which deposits a pharmaceutical formulation intranasally). Topical  
5 application of the virus to an airway surface can also be carried out by inhalation administration, such as by creating respirable particles of a pharmaceutical formulation (including both solid particles and liquid particles) containing the virus as an aerosol  
10 suspension, and then causing the subject to inhale the respirable particles. Methods and apparatus for administering respirable particles of pharmaceutical formulations are well known, and any conventional technique can be employed.

15 In another embodiment, the present invention relates to antibodies specific for the above-described virus. For instance, an antibody can be raised against any of the viral proteins or against a portion thereof. Persons with ordinary skill in the art using  
20 standard methodology can raise monoclonal and polyclonal antibodies to a polypeptide of the present invention. Material and methods for producing antibodies are well known in the art (see for example Goding, in, Monoclonal Antibodies: Principles and  
25 Practice, Chapter 4, 1986). The antibodies can be used to monitor the presence or activity of alphaviruses and potentially as a therapeutic agent.

In a further embodiment, the present invention relates to a method of detecting the presence of WEE,  
30 EEE, VEE IIIA or VEE IE viral infection or antibodies against these viruses, if present, in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a

microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of WEE, EEE, VEE IIIA or VEE IE virus described above, and contacting it with the serum of a person suspected of having a viral infection. The presence of a resulting complex formed between the virus and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as colorimetry or microscopy. This method of detection can be used, for example, for the diagnosis of WEE, EEE, VEE IIIA and VEE IE viral infections.

In yet another embodiment, the present invention relates to a method of detecting the presence of WEE, EEE, VEE IIIA or VEE IE viruses in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), antibodies specific for WEE and/or VEE IE, and contacting it with serum or tissue sample of a person suspected of having a WEE or VEE IE viral infection. The presence of a resulting complex formed between virus in the serum and antibodies specific therefor can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis of WEE, EEE, VEE IIIA and VEE IE viral infection.

In another embodiment, the present invention relates to a diagnostic kit which contains WEE, EEE, VEE IE, or VEE IIIA virus and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to WEE and VEE IE in serum or a tissue sample. Tissue samples

contemplated can be obtained from birds, monkey, human, or other mammals.

In yet a further embodiment, the present invention relates to DNA or nucleotide sequences for use in detecting the presence or absence of WEE, EEE, VEE IE or VEE IIIA virus using the reverse transcription-polymerase chain reaction (RT-PCR). The DNA sequence of the present invention can be used to design primers which specifically bind to the viral RNA for the purpose of detecting the presence, absence, or quantitating the amount of virus. The primers can be any length ranging from 7-40 nucleotides, preferably 10-15 nucleotides, most preferably 18-25 nucleotides. Reagents and controls necessary for PCR reactions are well known in the art. The amplified products can then be analyzed for the presence or absence of viral sequences, for example by gel fractionation, with or without hybridization, by radiochemistry, and immunochemical techniques.

In yet another embodiment, the present invention relates to a diagnostic kit which contains PCR primers specific for WEE, EEE, VEE IE or VEE IIIA and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence or absence of WEE, EEE, VEE IE or VEE IIIA in a sample using PCR. Samples contemplated can be obtained from birds, human, or other mammals.

In another embodiment, the present invention relates to a method of reducing WEE, EEE, VEE IE, or VEE IIIA viral infection symptoms in a patient by administering to said patient an effective amount of anti WEE, anti EEE, anti VEE IE, or anti VEE IIIA antibodies, or protective serum from an immunized animal. When providing a patient with antibodies, the dosage of administered agent will vary depending upon

such factors as the patient's age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of the above compounds  
5 which is in the range of from about 1pg/kg to 10 mg/kg body weight of patient, although a lower or higher dosage may be administered.

In another embodiment, the present invention relates to a method for overcoming vaccine  
10 interference in alphavirus-immune individuals. Alphavirus interference has been documented in animals and people since the 1960's. This phenomenon occurs when a live-attenuated vaccine is administered to animals or people with existing immunity to  
15 heterologous alphaviruses. Pre-existing immunity may be acquired by vaccination or infection. This presents a significant limitation to the usefulness of the current live-attenuated alphavirus vaccines, especially since the cross-reactive immunity does not  
20 protect adequately against challenge with virulent heterologous alphaviruses. Formalin-inactivated vaccines are not an acceptable alternative as they have significant limitations with regard to the quality and duration of protective immunity and  
25 require multiple inoculations and periodic boosters. The attenuated WEE, EEE, VEE IIIA and VEE IE virus vaccines of the present invention contain mutations in the viral glycoprotein sequences that may alter the sequence, conformation, and/or accessibility of cross-  
30 reactive epitopes. Alterations in epitopes that prevent binding by cross-reactive antibodies may also bypass interference in alphavirus-immune individuals. Eliminating the problem of interference would permit the WEE and VEE IE attenuated virus vaccines to be  
35 used in alphavirus-immune animals or people to induce

protective immunity to western equine encephalitis virus and/or to Venezuelan equine encephalitis virus variant IE. Long-lasting protective immunity to both parenteral and aerosol challenge would be expected after vaccination with the live-attenuated vaccines of the present invention, and provide an additional advantage over the use of inactivated vaccines which induce short-lived responses that do not protect against mucosal challenge.

Having now described the invention, the following examples are provided to illustrate the present invention, and should not be construed as limiting thereof. In light of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art.

#### **Attenuated WEE**

The following materials and methods were used in the examples that follow.

Viruses and cells. Western equine encephalitis virus, strain CBA/87 (Bianchi et al. 1988) and eastern equine encephalitis virus, strain Fla91-4679 (Mitchell et al. [1992] *Science* **257**:526-7) were grown in BHK cells in EMEM containing 10% fetal bovine serum, 100 U/ml penicillin G and 100 µg/ml streptomycin. Primary chicken embryo fibroblasts were grown in EMEM containing 5% fetal bovine serum. Baby hamster kidney cells and Vero cells were grown in EMEM containing 10% fetal bovine serum.

cDNA cloning. Genomic RNA was prepared from purified virus by phenol:chloroform extraction and ethanol precipitation. Initially, cDNA was prepared by the method of Gubler and Hoffman ([1983] *Proc.*

Natl. Acad. Sci. U.S.A. **85**:5997-6001). Subsequently, DNA representing the entire genome was prepared by polymerase chain reaction using a series of primer pairs (Table 1, Figure 1) based upon the partial genome sequences previously deposited in GenBank. Each PCR product was cloned into pCRII (Invitrogen). The 5' terminal sequence of CBA/87 virus was determined by 5'-RACE basically as described by Frohman et al. ([1988] *Proc. Natl. Acad. Sci. U.S.A.* **85**:8998-9002). The oligonucleotide, CBA/87 5', consisted of an SstII site, the promoter for bacteriophage T7 RNA polymerase followed by one G and 14 nucleotides of the 5' terminus of CBA/87 terminal sequence was paired with ns1962 and used to amplify the terminal 1.9 kb of the WEE genome. Clone pWE2000 representing the entire genome was assembled in pBluescript KS+ through the use of convenient restriction endonuclease sites.

20	<u>Table 1. Oligonucleotide Primers for Preparation of WEE PCR Products</u>	
	CBA/87 -T7-Sst2	
	GTCACCGCGGTAATACGACTCACTATAGATAGGGCATGGTATAGAG (SEQ ID NO:4)	
25	NS1962	TCACCTTATTCTGGAACACATCAG (SEQ ID NO:5)
	WEE-7	TCGGAGGAAGGCTGATGAAAC (SEQ ID NO:6)
	WEE-10	TCGGATCCGATGAGAAAATATACGCTCCC (SEQ ID NO:7)
	WEE-17	GACTGGATCCGCAAACCGTCCTGTTCTCAGG (SEQ ID NO:8)
30	WEE-18	GCATGGATCCAGCATGATCGGAAATGTCTTGTC (SEQ ID NO: 9)
	WEE-5	TCGGATCCACCGCCAAAATGTTTCCATAC (SEQ ID NO:10)
	WEE-3	TCGGGATCCCCGGAACATTTGGC (SEQ ID NO:11)
	WEE-2	CTGCTTTTCATGCTGCATGCC (SEQ ID NO:12)
35	WEE-Not	CGATGCGGCCGCTTTTTTTTTTTTTTTTGAATTTTAAAAAC (SEQ ID NO:13)
	WEE-CL2	CAGCGTGAAGTCATCGGTAATGCTGCGTGATGGACATTTCAAG (SEQ ID NO:14)
40	WEE-CL1	CAGCGTGAAGTCATCGGTAATGCTTGATGGACATTTCAAG (SEQ ID NO:15)



For ease of subsequent site-directed mutagenesis of the structural protein genes, two cassettes representing the 5' terminal 7.6 kb, plasmid pWE5'-18, and 3' 4.2 kb, plasmid pWE3'-17, of the genome were prepared. Full length clones were assembled by digestion of the pWE5'-18 with *BlnI* and *NotI* and insertion of a 4.1 kb *BlnI*-*NotI* fragment prepared from the plasmid pWE3'-17 or its mutagenized derivatives.

A cassette containing the structural genes of eastern equine encephalitis virus strain Fla91-4679 was prepared by RT-PCR. The cassette was digested with *BlnI* and *NotI* and the 4.0 kb fragment was ligated to pWE5'-18 which had been similarly digested. The resulting plasmid was designated pMWE-7.

Mutagenesis of the furin cleavage site. Two oligonucleotides, WEE-CL2 and WEE-CL which bracket the presumed furin cleavage site, RRPKR, between the E3 and E2 glycoproteins were used to delete the 5 and 4 codons, respectively. Plasmid pWE3'-17 was used as template for mutagenesis. WEECL2 and WEECL were paired with primer WEE-5 to generate PCR products of 1.4 kb. The PCR products were purified and paired with WEE-3 for 10 cycles of PCR utilizing WE3'-17 as template. Additional WEE-5 primer was added to 500 nM and PCR was carried out for an additional 20 cycles. The 2.3 kb products were purified, digested with *BstEII* and *NcoI* and ligated into plasmid pWE3'-17 which had been digested with *BstEII* and *NcoI*. Clones containing the mutation were identified by loss of the *NgoM1* site in the sequences encoding the furin cleavage site. The sequences of the mutations were confirmed by sequencing and the mutagenized pWE3'-17 cassettes were ligated to pWE5'-18 as described above to yield full length clones pWE2200 and pWE2100, respectively.

Identification of secondary mutations in virus  
derived from pWE2100 and pWE2200. Virus released from  
cells electroporated with RNA transcribed from pWE2200  
were plaque-purified and grown into stock  
5 preparations. Supernatant from cells transfected with  
RNA transcribed from pWE2100 was diluted 10-fold and  
inoculated onto BHK cells. The supernatant was  
collected 48 hours later and the RNA was extracted  
directly from the culture fluid. For each mutant  
10 virus and the parent CBA/87 virus, viral RNA was  
extracted with Trizol LS (Life Technologies, Inc.,  
Gaithersburg, MD) and the glycoprotein genes of each  
were amplified by reverse transcription-polymerase  
chain reaction amplification. The PCR products were  
15 purified (PCR Prep, Promega Inc., Madison, WI) and  
sequenced on an ABI 373 sequencer using fluorescent-  
tagged terminators.

Transcription and transfection. Purified plasmid  
was digested with NotI, phenol extracted and ethanol  
20 precipitated. Typically 0.5-1 ug of linearized DNA  
was transcribed *in vitro* by T7 RNA polymerase  
(Ribomax, Promega, Madison, WI) in the presence of 3  
mM m7GpppGp (Pharmacia, Piscataway, NJ).  
Electroporation of BHK or CEF cells with 0.4 ug of RNA  
25 was done as described (Liljestrom et al. [1991]  
*Bio/Technology* 9:1356-1361). The cells were then  
seeded into T-75 flasks with 20 ml of medium and  
observed for cytopathology at 24 and 36 hours after  
electroporation. Virus was harvested when the cells  
30 displayed significant cytopathology and approximately  
50% were detached from the plastic. Virus titers were  
determined by plaque assay on Vero and BHK cells.

**EXAMPLE 1****Preparation of an infectious clone of WEE strain CBA/87.**

One goal of this study was to prepare a full  
5 length cDNA clone of fully virulent WEE virus such  
that mutations leading to an attenuated phenotype  
could be identified. WEE, strain CBA/87, isolated  
from the brain of an infected horse in Argentina in  
1987 (Bianchi et al. [1988] *Am. J. Trop. Med. Hyg.*  
10 **49:322-328**), was chosen as the parent virus as it  
consistently kills 100% of 5 week old C57BL6 mice when  
inoculated subcutaneously, allowing development of a  
convenient animal model to assess the relative effects  
on virulence of the attenuating mutations. Portions  
15 of the sequence of several strains of WEE virus had  
been determined previously and were used as a basis  
for primers to prepare amplification products  
representing the entire genome of the CBA/87 which  
were cloned in pCRII. Full length clones were  
20 assembled in pBluescript KS+ using convenient  
restriction sites as shown in Figure 1. The first  
infectious clone pWE1000, contained the 5' terminal 20  
nucleotides from eastern equine encephalitis virus.  
This clone produced viable virus which was highly  
25 attenuated exhibiting an subcutaneous LD<sub>50</sub> in mice of  
approximately  $1.2 \times 10^6$  PFU compared to the CBA/87  
parent virus where LD<sub>50</sub> was approximately 22.

A second clone with an authentic WEE 5'-terminus,  
pWE2000, was used for all subsequent experiments.  
30 Transfection of CEF or BHK cells with RNA transcribed  
from pWE2000 resulted in complete destruction of the  
monolayers within 36 hours and titers  $>10^8$  PFU/ml were  
obtained by infection of either cell type with the  
resulting virus. Subcutaneous inoculation of 5 week

old C57/Bl6 mice with WE2000 results in death within 9 days and the LD<sub>50</sub> of 75 PFU is only slightly higher than the LD<sub>50</sub> of 22 PFU of CBA/87 parent virus, Table 2. It should be noted that animals surviving the lower doses of virus challenge gave no serological evidence of infection. This level of virulence for WE2000 virus was considered sufficient to allow for further characterization of the mutations necessary for attenuation of the virus.

10

Table 2. C57 Black/6 Mice Inoculated Subcutaneously with CBA/87 Parental virus and WE2000 Recombinant Virus

<u>Virus Strain</u> Dose	Mortality	Mean Day to Death (Days)	Prechallenge ELISA	Challenge (S/T)
<u>CBA/87</u>				
3X10 <sup>5</sup>	10/10	8.4	-	-
3X10 <sup>4</sup>	10/10	8.9	-	-
3X10 <sup>3</sup>	10/10	9.2	-	-
3X10 <sup>2</sup>	7/10	9.9	<100	0/3
3X10 <sup>1</sup>	3/10	10	<100	0/7
3	0/10	--	<100	0/10
<u>WE2000</u>				
1X10 <sup>7</sup>	10/10	8.7	-	-
1X10 <sup>6</sup>	10/10	9.0	-	-
1X10 <sup>5</sup>	10/10	9.2	-	-
1X10 <sup>4</sup>	10/10	9.3	-	-
1X10 <sup>3</sup>	9/10	10.0	<100	0/1
1X10 <sup>2</sup>	3/10	10.0	<100	0/7
1X10 <sup>1</sup>	0/10	-	<100	0/10
1	0/10	-	<100	0/10

15

## EXAMPLE 2

### Preparation of cleavage mutants of CBA/87.

Davis et al. ([1995] *Virology* 212:102-110) have demonstrated that deletion of the furin cleavage site between E3 and E2 glycoproteins of VEE virus is a lethal mutation. However, prolonged incubation of cells which had been transfected with RNA derived from

20

full length clones with the deletion, resulted in the eventual appearance of virus which was replication-competent and attenuated in mice (Davis *et al.*, 1995, *supra*). Based upon a comparison of the predicted structural protein sequences of WEE and VEE, the probable cleavage site of CBA/87 virus is RRPKR. The presence of the extra arginine when compared to the consensus (RX(R/K)R) alphavirus cleavage site indicated that the cleavage site of WEE virus might be more complex than that observed with VEE virus. We therefore, prepared two different deletion mutations in the E3-E2 cleavage site of the pWE2000 clone, pWE2100 which lacks five amino acids, RRPKR, and pWE2200 which lacks four amino acids, RPKR.

Development of CPE in cells after electroporation of RNA transcribed from pWE2100 and pWE2200 was delayed for 48 to 72 hours compared with pWE2000. In two instances, pWE2100 did not induce significant CPE in the transfected cells despite the fact that approximately  $10^6$  PFU/ml were released into the medium of transfected cells. When assayed by plaque formation on Vero cells, both supernatants yielded extremely small plaques after 72 hours which never increased beyond 2 mm in diameter. In contrast, pWE2000 virus yields large plaques after 48 hours which enlarge to approximately 1 cm after 5 days under a 0.5% agarose overlay. The small plaque phenotype of the mutant viruses is stable after 3 passages in Vero or BHK cells, which is the limit to the passage of the virus used in these experiments.

Analysis of the structural proteins of the WE2100 and WE2200 viruses by SDS-PAGE (Figure 2) shows that in each instance, the deletions at the cleavage site result in a virus which lacks E2 protein and contains a larger protein, presumably pE2, indicating that

deletion of the presumed cleavage site eliminated cleavage at this site.

The lack of rapid cytopathology after transfection of BHK cells with transcripts of pWE2200 and pWE2100 suggested that the mutants were non-viable and that the infectious virus subsequently detected by plaque assay was due to secondary mutations arising during the replication of the RNA as reported previously for deletion mutants of VEE (Davis et al., 1995, *supra*).

Three plaque isolates from WE2200 virus were chosen for further characterization. All isolates grew to high titer and exhibited a small plaque phenotype. The isolates were sequenced over the entire glycoprotein reading frame. As shown in Table 3, isolates 2215 and 2220 have a mutation of Glu to Lys at position 181 of the E2 glycoprotein. Strain WE2219 carries a single Glu to Lys at position 182 of the E2 protein. Strain WE2215 also has a conservative Val to Ala change at position 211 of the E2 glycoprotein. WE2220 has a Glu to Gly change at position 2 of the E1 glycoprotein and a Phe to Ser change at position 382 of the E1 glycoprotein.

Table 3. Genotypes of Recombinant WEE Virus Strains

<u>Virus<sup>1</sup></u>	<u>Cleavage Site</u>	<u>E2<sup>2</sup></u>	<u>E1<sup>2</sup></u>
CBA/87	RRPKR	P(102), E(181), E(182)	E(2), F(257), P(382)
vWE2100	-----	K(182)	
pWE2102	-----	K(182)	
vWE2215	R-----	K(181), A(211)	
vWE2219	R-----	K(182)	
vWE2220	R-----	K(181)	G(2), S(382)

1. p indicates viruses prepared by mutagenesis of infectious clones.

2. Amino acid at position indicated in parenthesis.

5        In order to determine a consensus of the mutations appearing in virus produced from the pWE2100 RNA, the sequences of the glycoprotein genes were determined directly from cDNA prepared by RT-PCR of the genomic RNA extracted from virus released from BHK  
10 cells infected with virus released from the transfected cells. Sequence analysis of glycoprotein genes of WE2100 virus from the transfection supernatant revealed only two mutations. As seen previously in WE2219, WE2100 also had a Glu to Lys  
15 change at position 182 of the E2 glycoprotein (Table 3).

         In order to determine which of the mutations identified in virus released from cells transfected with RNA transcripts from pWE2200 and pWE2100 served  
20 as the suppressor of the lethal effect of the cleavage deletion mutation, the mutations were individually placed into the pWE2200 and pWE2100 clones by site-directed mutagenesis. As shown in Table 4, three subclones of WE2200 were produced, and based upon the  
25 ability to induce CPE in BHK cells, it was demonstrated that the Glu to Lys change at position 181 of the E2 glycoprotein was necessary and sufficient to restore the ability of the WE2200 clone to encode replication competent virus. Similarly,  
30 placement of the Glu to Lys change at position 182 of the E2 glycoprotein was also sufficient to restore the ability of the WE2100 clone to encode replication competent virus. When the Glu to Lys changes at E2 position 181 or 182 were inserted into the parental  
35 infectious clone pWE2000, the resulting virus

exhibited a small plaque phenotype on Vero cells as noted for each of the cleavage deletion mutants.

5 Table 4. Effect of site-directed mutagenesis on restoration of cytopathogenicity of pWE2200 and pWE2100

	Strain	Cleavage site	E2	E1	Viability
	pWE2000	RRPKR			Yes
10	pWE2200	R----			No
	pWE2221	R----		G(2)	No
	pWE2222	R----	K(181)	G(2)	Yes
15	pWE2223	R----	K(181)		Yes
	pWE2100	-----			No
	pWE2102	-----	K(182)		Yes

20

Although the cleavage deletion mutations in pWE2200 and pWE2100 differed by a single amino acid, the results indicate that the mutations at E2 residues 181 and 182 are both capable of restoring viability of  
 25 the virus and appear to be equivalent.

### EXAMPLE 3

#### Attenuation of WE2000 virus.

C57/BL6 mice are uniformly susceptible to lethal  
 30 challenge by western equine encephalitis virus until approximately 9 weeks of age. Subcutaneous inoculation of five- or eight-week-old C57/BL6 female mice with CBA/87 or WE2000 viruses routinely results in lethal encephalitis after 8-9 days (Table 2). As  
 35 noted previously, the WE2000 is slightly less virulent than the CBA/87 parent. The virulence of the progeny virus derived from pWE2100 and pWE2200 infectious clones were determined by subcutaneous inoculation of C57BL6 mice. In each instance, the viruses were



significantly attenuated compared to virus produced from parent WE2000 clone. However, infection of mice with increasing doses of WE2215, WE2219 or WE2220, resulted in sporadic deaths with slightly extended periods prior to death compared to the parental virus (Table 5). These results indicated that deletion of only four amino acids from the cleavage site was inadequately attenuating, unlike the results obtained with VEE virus by Davis et al. (1995) and the viruses derived from WE2200 were not characterized further.

Table 5. C57BL6 Mice Inoculated Subcutaneously with WE2200 Cleavage Deletion Mutants

<u>Virus Strain</u> Dose	Mortality	Mean day to Death	Prechallenge ELISA	Neut	Challenge length	Post Challenge ELISA	Neut
<u>CBA/87</u>							
10 <sup>3</sup>	10/10	9.1					
10 <sup>5</sup>	10/10	7.7					
<u>WE2000</u>							
10 <sup>3</sup>	10/10	9.2					
10 <sup>5</sup>	10/10	9.1					
<u>WE2215</u>							
10 <sup>3</sup>	1/10	12	504 (3/9)	<20 (9/9)	8/9	8300	761
			100 (6/9)				
10 <sup>5</sup>	1/10	14	253 (7/9)	<20 (9/9)	9/9	12800	403
			100 (2/2)				
<u>WE2219</u>							
10 <sup>3</sup>	0/10	-	283 (2/8)	<20 (10/10)	6/10	14368	2281
			100 (6/8)				
10 <sup>5</sup>	2/10	12	200 (4/8)	<20 (8/8)	8/8	11738	1522
			100 (4/8)				
<u>WE2220</u>							
10 <sup>3</sup>	1/10	11	606 (5/9)	20 (3/9)	5/9	14703	1280
			100 (4/9)	<20 (6/9)			
10 <sup>5</sup>	2/10	14	800 (7/8)	20 (2/8)	8/8	9051	761
			100 (1/8)	<20 (6/8)			

When C57BL6 mice were inoculated subcutaneously with the uncloned WE2100 progeny virus, there were no deaths at any dilution, even at doses of  $10^7$  PFU per mouse (Table 6). However, some of those mice inoculated subcutaneously with  $10^5$  PFU or less remained susceptible to a lethal challenge with the virulent CBA/87 virus.

Table 6. C57 Black/6 Mice Inoculated Subcutaneously with WEE Virus Strain WE2100

Virus strain	Dose	Mortality <sup>1</sup> (%)	Mean Day to Death	Challenge <sup>2</sup> (%)
<u>WE2100</u>				
	$10^3$	0/10 (0)	-	4/10 (40)
	$10^4$	0/10 (0)	-	7/10 (70)
	$10^5$	0/10 (0)	-	8/10 (80)
	$10^6$	0/10 (0)	-	10/10 (100)
	$10^7$	0/10 (0)	-	10/10 (100)

1. Expressed as animals dying/animals tested  
2. Expressed as animals surviving/animals tested

WE2102 virus was demonstrated to be highly attenuated and killed only two of twenty mice when inoculated subcutaneously with the highest dosage of virus ( $10^7$  PFU). All mice were challenged 3 weeks later with  $10^5$  PFU of CBA/87 virus. Mice previously immunized with  $10^5$  PFU or more of WE2102 survived with no noticeable symptoms. Thus, an effective immunizing dose of WE2102 is at least 100 fold less than that required to kill C57BL6 mice. These results further indicate that the Glu to Lys change at position 182 of the E2 glycoprotein is responsible for restoring viability to viruses containing a deletion of the furin cleavage site in the WEE glycoproteins and that WE2102 virus is an effective attenuated vaccine virus.

Table 7. Subcutaneous Inoculation of C57BL/6 Mice with recombinant WEE virus strain 2102 confers protection against a lethal challenge

5

<u>Virus Strain</u>	<u>Mortality<sup>1</sup></u> (%)	<u>Mean Day to Death</u>	<u>Challenge<sup>2</sup></u> (%)
Dose			
<b><u>WE2100</u></b>			
10 <sup>3</sup>	0/10 (0)		3/10 (30)
10 <sup>5</sup>	1/10 (10)	16	9/9 (100)
10 <sup>7</sup>	0/10 (0)		10/10 (100)
<b><u>WE2102</u></b>			
10 <sup>3</sup>	0/20 (0)	-	9/20 (45)
10 <sup>5</sup>	0/20 (0)	-	18/20 (90)
10 <sup>7</sup>	2/20 (0)	14	18/18 (100)
<b><u>WE2000</u></b>			
10 <sup>5</sup>	10/10 (100)	9.2	

1. Expressed as animals dying/animals tested
2. Expressed as animals surviving/animals tested

10

#### Attenuated VEE IE

##### EXAMPLE 4

Sequence Analysis. Genomic RNA from VEE IE Strain 68U201 was isolated and reverse transcription of the genomic RNA followed by polymerase chain reaction (RT-PCR) was used to generate cDNA of the virus. Initial sequencing of the strain 68U201 genome employed oligonucleotide primers based on existing VEE IE sequence and VEE IA/B sequence. After a partial sequence of strain 68U201 was determined, oligonucleotides specific to the strain 68U201 sequence were used to obtain a complete sequence of the strain 68U201 viral genome. The exact 5' end of the genome was determined by PCR/RACE technique (Frohman et al. [1988] *Proc. Natl. Acad. Sci. U.S.A.* 85:8998-9002). The entire strain 68U201 viral genomes consists of 11,464

15

20

nucleotides, excluding the poly-A sequence (Oberste et al. [1996] *Virology* **219**: 314-320).

#### EXAMPLE 5

##### 5      Construction of Full-length, Live Clones

Using oligonucleotides specific to the VEE IE strain 68U201 sequence, RT-PCR of strain 68U201 viral RNA was carried out to generate numerous cDNA fragments that were subsequently cloned. These clones were used to assemble a full-length cDNA of strain 68U201 in a plasmid situated such that the cDNA could be precisely transcribed in an *in vitro* transcription reaction employing T7 polymerase. The first nucleotide downstream of the T7 promoter is a G followed by a cDNA encoding the entire strain 68U201 genome, including poly-A sequence. For the purposes of run off *in vitro* transcription, a unique endonuclease restriction site (*NotI*) follows the poly-A sequence (Figure 4). DNA sequences encoding the T7 promoter and the strain 68U201 genome were cloned into a suitable plasmid for propagation and selection in *E. coli*. Oligonucleotides relevant to construction of full-length infectious clones are shown in Table 8.

##### 25      Table 8

	0077	CTAAGAGGGGCCCTATATC (SEQ ID NO:16)
	0111	GCGGAATTCTAATACGACTCACTATAGATGGGCGGCATGAGAG (SEQ ID NO:17)
30	0113	TGACCGCGGGACCTCTGTCCAC (SEQ ID NO:18)
	0126	AAGTGCATCGATTTCAGCG (SEQ ID NO:19)
	0136	CTGAAATGTCCAGGATCCACGGAGGAGCTG (SEQ ID NO:20)
	0137	CAGCTCCTCCGTGGATCCTGGACATTTTCAG (SEQ ID NO:21)
	0140	GACTGCGGCCGCTTTTTTTTTTTTGAATATTAAAAACAAAATCC (SEQ ID NO:22)
35	0220	CGAGAATCGATGCACTTCAGCC (SEQ ID NO:23)

Descriptions of oligonucleotides are as follows:  
0077 introduces an *Apa*I endonuclease restriction site along with a serine to proline mutation within the coding region of nsP4. 0111 encodes an *Eco*RI  
5 endonuclease restriction site followed by the T7 promoter, a single G, and the first 18 nucleotides of the VEE IE genome. 0126 introduces a *Cla*I endonuclease restriction site within the coding region of nsP3 and was used in combination with 0220. 0113  
10 was used to remove an *Apa*I endonuclease restriction site within the structural genes. 0140 encodes a unique *Not*I endonuclease restriction site followed by a 12 T's, and the reverse complement of the last 21 nucleotides of the VEE IE. A *Not*I site at the end of  
15 the cDNA encoding the VEE IE genome allowed for run-off transcription after digestion of the plasmid with *Not*I. 0220 introduces a *Cla*I endonuclease restriction site within the coding region of nsP3 and was used in combination with 0126. Minor alterations of the  
20 nucleotide sequence using 0077, 0113, 0126, and 0220 facilitated assembly of the full-length clones and allowed for rapid diagnostic analysis of virus generated from these clones by RT/PCR methods.

The full-length clone obtained, pIE1006, was  
25 transcribed *in vitro* using T7 polymerase of *Not*I-linearized plasmid and the RNA transfected into BHK-21 cells (Figure 4). The phenotype of the resulting virus was markedly different from the parent virus (strain 68U201) from which the cDNA was derived. The  
30 virus derived from pIE1006 *in vitro* transcribed RNA, VIE1006, gave rise to small plaques upon infection of target monolayers (Table 9). In attempts to recover the phenotypic characteristics of strain 68U201, regions of the pIE1006 clone were replaced with cDNA  
35 generated by RT-PCR from strain 68U201 RNA. Three

subsequent full-length, live clones were constructed by replacing pIE1006 sequences with 928, 4492, and 8130 nucleotides generated by RT-PCR of strain 68U201 RNA. These clones were designated pIE1007, pIE1008 and pIE1009; and viruses derived from these clones were designated VIE1007, VIE1008 and VIE1009, respectively. These clones are shown in Figure 4. The relevant cloning sites and genetic markers are indicated above each clone. Numbers indicate the corresponding nucleotides in the strain 68U201 genome. The T7 promoter is shown. Drawings are not to scale. Shaded areas represent regions of pIE1006 that were replaced or mutated to generate new clones. The characteristics of these viruses are described below.

#### EXAMPLE 6

Assessment of Viruses Derived from Various Clones. The viruses VIE1006, VIE1007, VIE1008 and VIE1009 were derived from plasmids pIE1006, pIE1007, pIE1008, and pIE1009, respectively. Analysis of virus derived from these clones by plaque assay is shown in Table 9. Plaque size was determined by infection of Vero cell monolayers followed by agarose overlay.

Analysis of virus derived from these clones (Table 9) by plaque assay indicated that VIE1007 gave the same plaque morphology as VIE1006 and therefore was not studied further. The VIE1008 produced larger plaques in comparison to VIE1006, and the VIE1009 virus gave rise to the largest sized plaques of the four viruses tested. Plaques generated by VIE1009 were similar to those produced by the parental virus, strain 68U201.

Table 9: In vitro analysis of virus derived from  
molecular clones of VEE IE strain 68U201

5	<b>Virus Strain<sup>1</sup></b>	<b>Plaque Size</b>
	VIE1006	small
	VIE1007	small
	VIE1008	medium
10	VIE1009	large
	VEE IE 68U201	large

#### **EXAMPLE 7**

15        In Vivo studies of VEE IE Vaccine Candidates. The  
distinct plaque morphologies of VIE1006, VIE1008, and  
VIE1009 suggested that these viruses may behave  
differently *in vivo*. To assess the relative virulence  
of the cloned derivatives of strain 68U201, mice were  
20 initially inoculated with subcutaneously VIE1006,  
VIE1008, and VIE1009 viruses (Table 10). Mice  
infected with VIE1006 and VIE1008 were not adversely  
affected by these viruses as assayed by the number of  
mice surviving the infection. VIE1009 proved to be as  
25 virulent as strain 68U201, causing death in all of the  
animals infected (Table 10). Immunogenicity of the  
different viruses inferred by the demonstration of a  
protective immune response and was determined by back  
challenge of surviving animals in the virulence assay  
30 with approximately  $10^4$  pfu of the virulent, parental  
virus, strain 68U201. Back challenge was performed  
four weeks after the initial inoculation.

Table 10: In vivo analysis of virus derived from molecular clones of VEE IE strain 68U201

5	<b>Virus</b>		
	<b>Strain<sup>1</sup></b>	<b>Mortality<sup>2</sup></b>	<b>Challenge<sup>3</sup></b>
	<b>VIE1006</b>	0/10	10/10
	<b>VIE1008</b>	0/10	10/10
	<b>VIE1009</b>	10/10	nd
10	<b>VEE IE 68U201</b>	nd	1/10

<sup>1</sup> Initial inoculation with approximately  $10^4$  PFU of each virus with the exception of VEE IE 68U201 which were left untreated until challenge phase of experiment.

<sup>2</sup> Expressed as animals dying/animals tested.

<sup>3</sup> Expressed as animals surviving/animals tested. All animals were challenged with approximately  $10^4$  PFU of VEE IE strain 68U201 four weeks after the initial inoculation.

#### **EXAMPLE 8**

Construction of a Full-length, Molecularly Attenuated VEE IE Clone. With the availability of a full-length virulent clone, specific attenuating mutations were introduced into the structural genes of the virus by site-directed mutagenesis. A deletion mutation was used instead of a point mutation because of the inability of viral RNA replication to repair such mutations. The glycoproteins of VEE IE are produced as a poly-protein precursor, PE2. The junction between the E3 and E2 proteins is cleaved by a furin-like cellular protease. The amino acid sequence of the presumed furin-like protease cleavage site of strain 68U201 is RGKR. The nucleotides encoding these four amino acids of the furin-like cleavage site between the E3 and E2



proteins were deleted from the pIE1009 clone and the resulting "cleavage deletion" clone was designated pIE1100. The oligonucleotides used to generate the cleavage deletion mutation are shown in Table 8.

5 Oligonucleotide 0136 encodes a cleavage deletion mutation that eliminates the four amino acid furin-like cleavage site found in PE2 and was used in combination with oligonucleotide 0137. 0137 encodes the reverse complement of 0136.

10 Transfection of RNA transcribed from pIE1100 into tissue culture cells required extended incubation periods before viral cytopathic effect became apparent in the cultured cells. This extended incubation period is indicative of transcripts from full-length  
15 clones possessing mutations that partially inhibit viral replication. However, such mutations can be suppressed by second-site mutations which arise randomly via the error prone process of alphavirus replication, resulting in variants with enhanced  
20 replication ability. In fact, the culture media from cells transfected with RNA transcribed from pIE1100 contained low titers of infectious virus, VIE1100, which could be amplified to high titer ( $4 \times 10^7$  PFU/ml) upon subsequent passage. Biochemical analysis showed  
25 that this virus had an uncleaved PE2 protein indicating that the cleavage deletion mutation totally prevented proteolytic processing of the surface E2 glycoprotein precursor. The efficacy of VIE1100 virus to serve as a vaccine was evaluated in mice as  
30 described below.

One specific suppressor mutation is thought to reside at nucleotide 10,181 of the VEE IE genome, a C to U nucleotide substitution resulting in an amino acid change from Serine to Leucine in the E1 protein  
35 position #57. Ability of this mutation to suppress the

lethal nature of the furin cleavage site deletion mutation was assessed. The cDNA of pIE1100 was mutated by changing nucleotide 10,181 from a C to T. This introduced a serine to leucine change at amino acid number 57 of E1, a mutation found within the stock of VIE1100. The resulting clone was designated pVIE1150. Transfection of RNA from pVIE1150 into BHK-21 cells lead to the production of approximately  $10^6$  PFU/ml of virus in the supernatant of the transfected cells at 48 hours post-transfection.

#### EXAMPLE 9

Vaccine Studies with a Full-length, Molecularly Attenuated Virus. Balb/C mice were inoculated with VIE1100 virus at various doses ( $10^4$ ,  $10^6$ , and  $10^7$  PFU per mouse), and was found to be completely attenuated at a dose 100,000 times higher than that required to cause lethal disease by the parent virus, strain 68U201 (Table 10). Subsequent challenge of these animals with virulent strain 68U201 demonstrated that immunization with VIE1100 virus provided complete protection from lethal virus challenge (Table 11).

Table 11: Vaccination study with VIE1100

25	Virus Strain Dose	Mortality <sup>1</sup>	Challenge <sup>2</sup>
30	<b>VIE1100</b>		
	$10^4$	10/10	10/10
	$10^6$	10/10	10/10
	$10^7$	10/10	10/10
	Mock Vaccinated	0/10	0/10

- 35 1. Expressed as animals dying/animals tested.  
2. Expressed as animals surviving/animals tested after inoculation with  $10^4$  PFU of VEE IE strain 68U201

**EXAMPLE 10**

Properties of a WEE-EEE chimeric virus. Based upon similarities of amino acid sequences of the carboxy terminal portion of NSP-4 and the amino terminal portion of the capsid proteins of WEE, EEE and Sindbis virus, it has been suggested that WEE virus arose by recombination between EEE and a Sindbis virus ancestor (Hahn et al. [1988] *Proc. Natl. Acad. Sci. U.S.A.* **85**: 5997-6001). The capsid genes of both WEE and EEE contain a highly conserved sequence with a unique Bln I site 76 nucleotides downstream of the initiation codon. We utilized this site to insert the structural protein sequences of EEE into pWE5-18 in order to construct a full length clone encoding a chimeric virus. Plasmid pMWE-7 is a full length clone consisting of the 5' non-coding sequence, nonstructural genes, 26S promoter and the first 25 codons for the capsid protein of WEE CBA/87 fused to the structural protein genes and 3' non-coding sequence of EEE strain Fla91-4679. Transfection of BHK cells with RNA transcribed from pMWE-7 resulted in complete destruction of the monolayer and release of high yields of virus. SDS-polyacrylamide gel electrophoresis of the purified virus demonstrated that the virus is composed of polypeptides which comigrate with those of EEE and not of WEE, indicating that the virus is a chimera (Figure 3).

Injection of mice with the MWE chimeric virus killed mice only sporadically, suggesting that fusion of the sequences of the two viruses resulted in significant attenuation compared to the parent WE2000 virus (Table 12). Mice immunized with MWE-7 developed significant neutralizing antibody titers and resisted a lethal EEE Fla91-1467 challenge when immunized with greater than  $10^5$  plaque forming units of

MWE-7 virus. The neutralizing antibody response after\* challenge was not significantly elevated indicating that the immunization with the chimeric virus effectively prevented infection by a lethal EEE challenge. Therefore, a chimeric virus derived by combining the structural protein genes of EEE with the non-structural proteins genes of WEE may serve as a safe, effective approach to development of a vaccine for EEE virus.

Table 12. Immunization of C57BL6 Mice with an WEE/EEE Chimeric Virus Confers Protection Against a Lethal EEE Challenge

<u>Virus Strain</u>	<u>Mortality<sup>1</sup></u>	<u>Mean Day to Death</u>	<u>Challenge<sup>2</sup></u>
<u>Dose</u>			
<u>WE2000</u>			
10 <sup>5</sup>	10/10 (100)	8.5	
<u>MWE7</u>			
10 <sup>3</sup>	0/10 (0)		6/10 (60)
10 <sup>5</sup>	1/10 (10)	8.0	9/9 (100)
10 <sup>7</sup>	0/10 (0) <sup>3</sup>		9/9 (100)
<u>Saline Control</u>	0/10 (0)		0/10 (0)

1. Expressed as animals dying/animals tested  
 2. Expressed as animals surviving/animals tested  
 3. One animal died during pre-challenge bleed

#### Example 12 VEE IIIA Chimera

##### Construction of IAB-IIIA cDNA Chimeric Clone (pV3A-1000)

BeAn8 (wild type Mucambo or VEE IIIA) cDNA was amplified with primers 128 and 140 (Table 13) to generate a PCR fragment of the entire 26S region of BeAn8. Primer 128 incorporated an ApaI site just upstream of the BeAn8 26S promoter to facilitate cloning into pV3000. Primer 140 introduced a NotI

site just downstream of the poly(A) tract which would also facilitate cloning into pV3000 as well as enable run-off transcription. This 128/140 PCR fragment was cloned into pBluescript SK+ vector using the ApaI and NotI sites and was termed pMUC-1000.

To replace the BeAn8 3' nontranslated region (3'NTR) in pMUC-1000 with the corresponding region in pV3000, an EcoRI site was introduced immediately downstream of the E1 stop codon in both pMUC-1000 and pV3000 using the primer pairs 013/227 and 225/226, respectively. The 013 primer is a universal primer found in the pBluescript SK+ vector and the 227 primer was designed to introduce an EcoRI site in pMUC-1000. The 225 primer introduced an EcoRI site in pV3000 and the 226 primer is located in the vector, TotoX. The 013/227 and 225/226 PCR fragments were separately cloned into the pBluescript SK+ vector producing pMUC-1200 and pV3nt-1000, respectively. The 3' NTR encoded in pV3nt-1000 was shuttled into pMUC-1200 using the EcoRI site and the NotI site to produce pMUC-1300.

The full-length chimeric cDNA clone, pV3A-1000, was constructed by shuttling the structural genes encoded in pMUC-1300 into the pV3000 nonstructural domain using the ApaI site and NotI site.

Table 13. Primers for construction of the pV3A-1000

013	--	AACAGCTATGACCATG (SEQ ID NO:24)
128	--	CTGAGAGGGGCCCCAGTAAC (SEQ ID NO:25)
140	--	GACTGCGGCCGCTTTTTTTTTTTTGAATATTAAAAA (SEQ ID NO: 26)
225	--	CCAGAAACATAATTGAATTCAGCAGCAATTG (SEQ ID NO:27)
226	--	CTTTATCCGCCTCCATCC (SEQ ID NO:28)
227	--	CCAATCGCTGCTGAATTCTAATTATGTTTCTG (SEQ ID NO:29)

Five week old C57BL6 mice were used in a challenge study (Table 14). All mice immunized with

10<sup>7</sup> PFU of pV3A-1000 produced neutralizing antibodies. Mice were challenged with 10<sup>7</sup> PFU of 900807 (a Mucambo virus from Trinidad). The geometric mean neutralizing antibody titer in mice inoculated with 10<sup>7</sup>, 10<sup>5</sup>, and 10<sup>3</sup> PFU of pV3A-1000 was 9800, 8800, and 7000 respectively.

Table 14. Results from challenge studies

	Fraction of mice sick/inoc	Fraction of mice dead/inoc	Average days to onset of illness	Average days to death
Immunized with pV3A-1000	0/20	0/20	N/A	N/A
Unvac- cinated	19/20	12/20	6.2	10.5

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5       (i) APPLICANT: Michael D. Parker  
                      Jonathan F. Smith  
                      Bruce Crise  
                      Mark Steve Oberste  
                      Shannon Schmura

10

         (ii) TITLE OF INVENTION: Live Attenuated virus  
          vaccines for western equine encephalitis virus,  
          eastern equine encephalitis virus, and venezuelan  
          equine encephalitis virus IE and IIIA variants

15

         (iii) NUMBER OF SEQUENCES:29

## (iv) CORRESPONDENCE ADDRESS:

20       (A) ADDRESSEE: John Moran  
         (B) STREET: USA MPMC - MPMC-JA  
         (C) CITY: FORT DETRICK, FREDERICK  
         (D) STATE: MARYLAND  
         (E) COUNTRY: USA  
         (F) ZIP: 21702-5012

25

## (v) COMPUTER READABLE FORM:

30       (A) MEDIUM TYPE: Floppy disk  
         (B) COMPUTER: Apple Macintosh  
         (C) OPERATING SYSTEM: Macintosh 7.5  
         (D) SOFTWARE: Microsoft Word 6.0

30

## (vi) CURRENT APPLICATION DATA:

35       (A) APPLICATION NUMBER:  
         (B) FILING DATE:  
         (C) CLASSIFICATION:

35

## (vii) PRIOR APPLICATION DATA:

40       (A) APPLICATION NUMBER: Provisional  
         Application 60/047162,  
         (B) FILING DATE: May 20, 1997

40

         (A) APPLICATION NUMBER: Provisional  
         Application 60/053,652

(B) FILING DATE: July 24, 1997

(viii) ATTORNEY/AGENT INFORMATION:

- 5 (A) NAME: Moran, John  
(B) REGISTRATION NUMBER: 26,313  
(C) REFERENCE/DOCKET NUMBER:

(ix) TELECOMMUNICATION INFORMATION

- 10 (A) TELEPHONE: (301) 619-2065  
(B) TELEFAX: (301) 619-7714

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 11492 base pairs  
(B) TYPE: Nucleic acid  
(C) STRANDEDNESS: Double  
(D) TOPOLOGY: Linear

20 (ii) SEQUENCE DESCRIPTION: SEQ ID NO:1:

1 ATAGGGCATG GTATAGAGGC ACCTACCCTA CAAACAAATC  
GATCCAATAT

25 51 GGAAAGAATT CACGTTGACT TAGACGCTGA CAGCCCATAT  
GTCAAGTCGT

101 TACAGCGGAC GTTTCACAA TTTGAGATCG AAGCAAGGCA  
GGTCACTGAC

30 151 AATGACCATG CCAATGCCAG AGCGTTTTTCG CATGTGGCAA  
CAAAGCTCAT

201 TGAGAGCGAA GTCGACCGGG ACCAAGTTAT CTTGGACATT  
GGAAGTGCGC

35 251 CCGTCAGACA TGCACATTCC AACCACCGCT ATCATTTGTAT  
CTGCCCCATG

40 301 ATAAGCGCTG AAGACCCGGA CAGACTACAG CGGTATGCAG  
AAAGACTTAA

351 GAGAAGTGAC ATGTACCGAC AAGAATATAG CCTCTNAAGG  
CGGCAGACCT

45 401 GCTGGAAGTC ATGTCCACAC CAGACGCAGA GACTCCATCT  
CTGTGTATGC

451 ACACAGACGC CACGTGTAGG TACTTTGGAA GTGTANGCAG  
TATACCAAGA

50



501 TGTGTACGCA GTCCATGCAC CGACATCAAT CTACCACCAG \*  
GCGCTTAAAG

5 551 GAGTTAGGAC AATTTACTGG ATAGGTTTTG ACACGACCCC  
TTTTATGTAC

601 AAAAACATGG CAGGTTCTTA CCCTACTTAC AACACAACT  
GGGCCGACGA

10 651 GAGAGTATTG GAAGCACGTA ACATTGGCCT CGGTA ACTCA  
GATCTTCAGG

701 AGAGCAGACT TGGAAAACCTT TCAATCCTTA GGAAGAAGAG  
GCTCCAACCT

15 751 ACTGATAAGA TCATATTCTC GGTGGTTCA ACAATCTACA  
CAGAGGATAG

801 ATCACTGTTA CGTAGCTGGC ATCTTCCAAA CGTGTTCCAC  
20 CTGAAAGGAA

851 AGTCTNACTT CACAGGTAGA TGTGGGACCA TTGTCAGCTG  
TGAAGGGTAT

25 901 GTCATCAAAA AGATAACGAT CAGCCCAGGA CTATACGGTA  
AAGTTGAGAA

951 CTTGGCGTCC ACGATGCATC GCGAGGGTTT CTTGAGTTGC  
AAAGTCACAG

30 1001 ATACGCTGCG CGGCGAGAGG GTTTCTTTTG CTGTGTGTAC  
GTATGTACCA

1051 GCCACACTTT GCGATCAGAT GACAGGGAGG GCTCAACCAA  
35 CGGATTGTCG

1101 TCAATGGTAG GACGCAAAGA AATACTNACA CAATGCAGAA  
CTATCTATTA

40 1151 CCAGTGGTCG CCCAGGCGTT TTCCAGGTGG GCGCGTGNAC  
ATCGTGCCGA

1201 CTTGGACGAC GAGAAGGAGC TAGGGGTGCG GGAGCGCACT  
CTTACTATGG

45 1251 GCTGCTGCTG GGCTTTCAAG ACCCAGAAAA TTACATCCAT  
CTACAAGAAG

1301 CCTGGTACGC AAACAAATTA AGAAAGTACC TGCCGTCTTT  
50 TGACTCATT

1351 GTGATTCCGA CGCCTTACCA GCCACGCGGG GGCTCGAATA  
TGGGCCTTCC

5 1401 GCCGTNAGGC TCAAGCTGCT GCTTGAACCA ACTGTCAAAC  
CCGCACCGGC

1451 TATTACAATG GCCGATGTGG AGCACCTGCG TGGCTTACAG  
CAAGAAGCTG

10 1501 AAGAAGTGGC TGCAGCGGGA AGAGATCAGA GAAGCCCTGC  
CACCTTGGCT

1551 CCCTGAAATA GAAAAAGAGA CCGTAGAGGC AGAAGTAGAC  
CTCATTATGC

15 1601 AAGAGGCAGG AGCAGGTAGC GTGGAGACAC CNACGAGGAC  
ATATCAAGGT

1651 AACAAAGTTAC CCAGGTGNAA GAGAAGATTG GGTCTTATCC  
CTATACTTTC

20 1701 ACCCCAGGCG GTTTTANAAT NGTNAAAAAC TGGCGTGTAT  
CCACCCATTG

25 1751 GCGGAACAAG TACTGGTAAT GACTCACAAA GGCAGGGCCG  
GGCGATACAA

1801 AGTCGAGCCA TACCACGGTA NGGTCATTGT ACCCAGAAGG  
GACGGCGGGT

30 1851 CCCTGTTCAA GACTTTCAGG CACTGAGTGA GAGCGCCACG  
ATCGTTTTCA

1901 ACGAGAGGGA GTTCGTAAAC CAGATATTTT GCACCCACAT  
CGCAAGCKTT

35 1951 TCAACTATAG TGAGTCGCTA TTACACTGAC GAAGAGTACT  
ATAAGATTGT

40 2001 AAAGACTCAG GACGCAGACT CAGAATACGT CTTTGACATT  
GACGCACGAA

2051 AGTGTGTTAA GCGAGAAGAC GCAGGTCCCT TGTGCCTAAC  
TGGTGATCTG

45 2101 GTAGATCCAC CATTTACGA GTTTGCGTAC GAGAGTCTCA  
AGACACGACC

2151 AGCAGCACCT CACAAAGTCC CAACCATCGG AGTCTATGGA  
50 GTGCCAGGTT

2201 CAGGTAAATC TGGGATCATC AAAAGCGCTG TGAATAAGAA  
AGATCTGGTT

2251 GTGAGTGCGA AGAAGGAAAA CTGCGCAGAA ATTATCAGGG  
5 ATGTAAGGAG

2301 GATGAGACGT ATGGATGTTG CTGCTAGGAC TGTTGATTCA  
GTGCTTCTAA

2351 ATGGGGTTAA GCACCCCGTT AACACCCTGT ACATTGATGA  
10 GGCATTGACC

2401 TGCCATGCAG GGACGCTGCT GGCACTGATT GCCATCGTCA  
AACCTAAGAA  
15

2451 AGTGGTATTG TGCAGGGGACC CAAAACAATG CGGCTTCTTT  
AACATGATGT

2501 GCCTGAAAGT ACATTTTAAAC CATGACATAT GCACTGAGGT  
20 GTACCACAAA

2551 AGCATCTCTA GGAGGTGCAC ACAGACTGTA ACCGCCATTG  
TCTCCACGCT

2601 CTTCTACGAC AAGCGAATGA AGACGGTTAA CCCATGTGCT  
25 GACAAAATCA

2651 TCATAGATAC CACAGGGACC ACAAAGCCGC ACAAAGATGA  
TCTGATTCTA  
30

2701 ACCTGTTTCA GAGGATGGGT GAAACAGCTA CAGATTGACT  
ATAAAAATCA

2751 TGAAATCATG ACTGCGGCTG CATCGCAAGG ACTTACGCGG  
35 AAAGGCGTTT

2801 ATGCTGTCAG GTACAAAGTC AACGAGAATC CACTCTACTC  
GCAGACTTCT

2851 GAGCACGTGA ACGTGTTAGT TACACGCACA GAAAAACGCA  
40 TTGTCTGGAA

2901 GACGCTAGCT GGTGACCCCT GGATAAAGAC ACTTACAGCT  
AAATACTCCG  
45

2951 GGGATTTTAC GGCTTCATTG GACGACTGGC AACGCGAACA  
CGACGCTATT

3001 ATGGCACGCG TTCTTGATAA GCCGCAGACA GCTGATGTGT  
50 TCCAGAATAA

3051 GGTGAACGTC TGCTGGGCGA AGGCTTTAGA GCCAGTCTTG  
GCCACGGCCA

5 3101 ACATTGTGCT GACGAGACAG CAGTGGGAGA CGTTGCACCC  
ATTCAAGCAT

3151 GACAGAGCGT ACTCACCTGA AATGGCACTG AACTTCTTTT  
GCACCAGGTT

10 3201 CTTTGGTGTA GACCTGGACA GTGGGTGTT TTCCGCTCCT  
ACCGTCGCAC

3251 TTACTTACAG GGATCAGCAC TGGGACAACT CGCCAGGGAA  
GAACATGTAT

15 3301 GGGCTTAATA GAGAGGTAGC AAAGGAGCTG TCACGGCGAT  
ATCCGTGCAT

3351 CACAAAAGCG GTTGACACAG GCAGGGTAGC TGATATAAGG  
20 AATAATACCA

3401 TCAAGGACTA CTCTCCAACA ATTAATGTGG TTCCATTAAA  
TCGCCGGTTG

25 3451 CCCCACTCGC TGATCGTTGA CCACAAAGGA CAGGGTACAA  
CTGATCACAG

3501 TGGATTCCTA TCTAAGATGA ATGGCAAATC TGTGTTGGTG  
ATCGGCGATC

30 3551 CTATCAGCAT TCCTGGGAAG AAAGTAGAGT CCATGGGTCC  
ATTGCCCACT

3601 AATACCATCA GGTGTGATCT CGATTGGGA ATACCTAGCC  
35 ATGTCGGTAA

3651 ATATGACATT ATATTTGTCA ATGTTAGGAC CCCATACAAG  
AACCATCACT

40 3701 ACCAACAGTG CGAGGATCAC GCTATCCACC ACAGCATGCT  
AACGTGTAAG

3751 GCTGTCCACC ACCTGAACAC TGGCGGAACA TGTGTGGCCA  
TAGGGTATGG

45 3801 ACTTGCTGAT CGCGCAACCG AGAATATCAT CACTGCGGTG  
GCTCGCTCAT

3851 TTAGGTTTAC CCGTGTCTGT CAGCCTAAGA ACACTGCCGA  
50 AAATACTGAG

3901 GTTCTCTTCG TGTTCTTCGG CAAGGACAAC GGCAACCACA  
CACATGACCA

3951 GGACAGACTC GGTGTAGTGC TTGACAACAT CTACCAAGGG  
5 TCAACCAGGT

4001 ACGAGGCAGG GAGAGCTCCA GCGTACAGAG TGATCAGAGG  
TGACATTAGC

4051 AAGAGCGCTG ACCAAGCTAT CGTTAATGCT GCTAATAGCA  
10 AAGGTCAACC

4101 AGGTTCCGGA GTGTGCGGTG CACTGTACCG AAAATGGCCG  
GCTGCTTTTG  
15

4151 ATAGACAGCC AATAGCTGTC GGGACGGCTA GACTTGTGAA  
GCACGAACCG

4201 CTCATCATAC ATGCTGTAGG ACCGAATTTT TCTAAGATGC  
20 CGGAACGAGA

4251 GGGCGACCTT AAGCTCGCAG CTGCCTACAT GAGCATAGCG  
TCCATCGTCA

4301 ACGCTGAGCG GATTACTAAA ATATCAGTAC CGCTACTGTC  
25 AACTGGCATC

4351 TATTCTGGTG GCAAAGATCG AGTGATGCAA TCATTGCATC  
ACTTGTTTAC  
30

4401 TGCTTTCGAC ACTACGGATG CCGATGTCAC CATATATTGC  
TTGGATAAAC

4451 AATGGGAGAC CAGGATAACC GAGGCCATTC ACCGCAAAGA  
35 AAGCGTCGAA

4501 ATACTGGATG ATGATGACAA GCCAGTAGAC ATCGACTTGG  
TCAGGGTCCA

4551 CCCAAACAGC TCTTTGGCAG GCAGACCAGG TTACTCCGTC  
40 AATGAGGGCA

4601 AGCTGTATTC ATACCTGGAA GGTACACGAT TCCATCAGAC  
CGCCAAGGAC  
45

4651 ATTGCCGAAA TCCATGCAAT GTGGCCCAAC AAATCTGAGG  
CTAATGAGCA

4701 GATTTGCTTG TACATCCTGG GGGAGAGTAT GTCCAGCATC  
50 CGCTCCAAAT

4751 GCCCAGTAGA GGAGTCAGAG GCGTCTGCTC CACCTCACAC  
ACTTCCATGC

4801 CTGTGTAATT ACGCTATGAC GGCTGAGCGC GTATACAGGT  
5 TGC GCTCTGC

4851 GAAGAAAGAA CAGTTCGCCG TATGCTCATC ATTCCCGTTG  
CCGAAGTACA

4901 GGATCACAGG CGTGCAGAAG CTACAGTGCA GCAAACCAGT  
10 CCTGTTCTCA

4951 GGCGTCGTAC CACCGGCTGT ACACCCCAGG AAGTACGCGG  
AAATAATTCT  
15

5001 AGAAACGCCA CCATCGCCAA CAACGACAAC CGTAATATGT  
GAACCAACTG

5051 TGCCAGAACG TATACCCAGT CCGGTGATTT CTAGAGCAGC  
20 AAGTGCGGAA

5101 TCACTGCTAT CGTTTGGCGG CGTCTCGTTC TCTAGCTCTG  
CCACACGCTC

5151 GTCAACTGCC TGGAGCGACT ATGACAGGCG GTTTGTGGTT  
25 ACAGCTGACG

5201 TGCATCAAGC GGACACGTCT ACGTGGAGCA TCCCTAGCGC  
TCCTGACTTG  
30

5251 GACGTCCAGC TGCCTTCTGA CGATACTGAT TCCCACTGGA  
GTATTCCGAG

5301 TGCATCAGGC TTTGAAGTGA GAACACCGTC TGTACAGGAC  
35 CTA ACTGCAG

5351 AGTGTGCGAG GCCTCGTGGA CTGGCCGAAA TAATGCAAGA  
CTTCAATACG

5401 GCTCCTTTCC AGTTTCTTTC GGACCACAGA CCAGTACCAG  
40 CACCACGGAG

5451 ACGCCCCATC CCATCACCTA GATCGACGGT TTCCGCACCT  
CCAGTTCCAA  
45

5501 AGCCACGCAG AACTAAGTAC CAACAACCAC CAGGAGTCGC  
TAGGGCGATC

5551 TCAGAAGCGG AGCTGGACGA GTACATCCGT CAACATTCCA  
50 ATTGACGGTA

5601 TGAAGCGGAG CGTATATTTC TCATCGAAAC AGGCCAGGTC  
ACCTTCAACA

5 5651 GAAATCAGTA CGTCAATGTA AACTACAAGA CCCTATATTG  
GAACGGGCCG

5701 TCCATGAGAA GTATTAGCCC CGCGCCTCGA TCTCGAAAGA  
GAGAAGATGT

10 5751 TACAGAAGAA ACTGCAATTA TCGCGCTCNT GAAGGAAATA  
GAAGCAGGTA

5801 TCAATCACGA AAAGTANGAA AATATGAAAG CAATTACAGC  
GGAGCGACTC

15 5851 ATTTCTGGAT TGGGCACATA TCTATCATCA GAAGTGAATC  
CTGTCGAGTG

5901 TTACAGAGTC AATTATCCTG TACCAATCTA CTCGTCAACG  
20 GTAGTTAATA

5951 GGTTTTTCATC AGCAGAAGTG GCCGTCAAAG TTTGCAACTT  
AGTCATCCAA

25 6001 GAGAATTACC CTACAGTAGC CAGTTATTGC ATAACAGATG  
AATACGATGC

6051 GTATCTTGAC ATGGTGTACG GCGCTCGTGC TGTTAGATAC  
AGCGCCTTTG

30 6101 TCCGCTNACT GAGAAGCTAC CCAAAGAAGC ATAGCTACTT  
GCAGCCAGAG

6151 ATAAGATCAG CTGTCCCATC ACCTATACAG AATACATTAC  
35 AAAATGTATT

6201 GCTGCAGCCA CTAAAAGGAA CTGCAACGTT ACCCAAATGC  
GAGAACTACC

40 6251 TGTTTTATTTC GGCGGCATTC AACGTTGAAT GTTTCAAGAA  
ATACGCATGC

6301 AATGATGAGT ATTGGGATAC CTTTCGCGAT AACCCATTTC  
GGCTAACTAC

45 6351 AGAGAACGTT ACGCAATACG TGACAAAGCT GAAAGGGCCG  
AAAGCAGCAG

6401 CATTATTTCGC AAAAATCTCAC AACCTAAAAC CGTTGCAGGA  
50 GATACCAATG

6451 GACGAATTTG TCATGGTCTN AAAAGAGATG TCAAAGTTAC  
TCCCGGCACA

5 6501 AAACATACAG AGGAGCGGCC TAAGGTGCAG GTTATTCAGG  
CTGCAGATCC

6551 TCTCTGTACC GCTTACCTTT GCGGGATCCA TCGAGAATGT  
CCGTAGACTG

10 6601 AATGCTGTGC TTCTGCCGAA TATCCATACT CTCTTCGACA  
TGTCAGCGGA

6651 AGATTTTGAT GCGATTATTG CTGAACATTT CCACCACGGC  
GACCCAGTAT

15 6701 TGGAAACGGA CATCGCGTCG TTTGATAAAA GCGAAGACGA  
CGCTATCGCC

6751 ATTTCTGGCGT TGATGATCCT CGAGGACTTA GCGTTCGACC  
20 AACCGCTCTT

6801 AGATTTGATA GAGGCGGCGT TCGGCAATAT CACATCTGTG  
CACCTACCTA

25 6851 CAGGAACGAG GTTCAAATTT GGTGCCATGA TGAAATCCGG  
TATGTTCTTA

6901 ACGCTGTTTG TCAACACACT AGTCAATATC ATGATTGCTA  
GCAGAGTACT

30 6951 ACGTGAACGG TTAACCACGT CAGAGTGCGC GGCCTTATCG  
GCGACAATAA

7001 CATAGTGCAC GGTGTCGCTC CGACAACTTG ATGGCGGAGA  
35 GATGCGCCAC

7051 TTGGCTGAAC ATGGAAGTAA AAATTATTGA TGCAGTCATT  
GGTATCAAAG

40 7101 CACCCTACTT CTGCGGGGAT TCATCCTGGT GGATCAGATA  
ACGACACAGC

7151 CTGTAGGTCG CAGACCCTCT AAAAAGGCTT TTTAAGCTTG  
GAAAACCATT

45 7201 GCCAGTCGAT GACACCCAAG ACTGTGACCG TCGCCGGGCA  
CTGCATGATG

7251 AAGCAATGCG ATGGAACAGA ATTGGAATTA CGGACGAGTT  
50 GGTGAAGGCC



7301 GTAGAATCCA GATACGAGAT CATACTGGCA GGCCTGATCA  
TCACGTCCCT

5 7351 GTCCACGTTA GCCGAAAGCG TTAAGAACTT CAAGAGCATA  
AGAGGGAACC

7401 CAATCACCTT CTACGGCTGA CCTAAATAGG TGACGTAGTA  
GACACGCACC

10 7451 TACCCACCGC CAAAAATGTT TCCATACCCT CAGCTGAACT  
TTCCACCAGT

7501 TTACCCTACA AATCCGATGG CTTACCGAGA TCCAAACCCT  
CCTAGGCGCC

15 7551 GCTGGAGGCC GTTTCGGCCC CCGCTGGCTG CTCAAATCGA  
AGATCTTAGG

7601 AGGTCGATAG CCAACTTAAC TTTCAAACAA CGATCACCTA  
20 ATCCGCCGCC

7651 AGGTCCGCCG CCGAAGAAGA AGAAGAGTGC TCCCAAGCCA  
AAACCTACTC

25 7701 AGCCTAAAAA GAAGAAGCAG CAAGCCAACA AGACGAAACG  
CAAGCCTAAA

7751 CCAGGGAAAC GACAGCGTAT GTGTATGAAG TTGGAGTCGG  
ACAAGACATT

30 7801 TCCGATCATG TTGAACGGCC AAGTGAATGG ATACGCTTGC  
GTTGTCTGGAG

7851 GAAGGCTGAT GAAACCACTC CACGTTGAAG GAAAAATCGA  
35 TAATGAGCAA

7901 TTAGCGGCCG TGAAATTGAA GAAGGCTAGC ATGTACGACC  
TGGAGTATGG

40 7951 CGACGTTCCC CAGAATATGA AATCAGACAC GCTGCAGTAC  
ACCAGCGACA

8001 AACCACCGGG CTTCTACAAC TGGCACCACG GCGCAGTCCA  
GTATGAGAAT

45 8051 GGGAGATTCA CCGTACCGCG AGGAGTGGGC GGGAAAGGCG  
ACAGTGGAAG

8101 ACCGATCCTG GACAACAGAG GCAGAGTTGT GGCTATTGTT  
50 CTAGGAGGTG

8151 CAAACGAGGG CACGCGTACG GCGCTTTCAG TGGTCACTTG  
GAACCAGAAA

5 8201 GGGGTGACCA TCAAGGATAC CCCC GAAGGT TCTGAACCGT  
GGTCACTAGT

8251 TACAGCGCTG TGC GTGCTTT CGAATGTCAC ATTCCCTTGC  
GACAAACCAC

10 8301 CCGTGTGCTA TTTACTGGCG CCAGAACGAA CACTCGACGT  
GCTCGAGGAG

8351 AACGTCGACA ATCCAAATTA CGACACGCTG CTGGAGAACG  
TCTTGAAATG

15 8401 TCCATCACGC CGGCCCAAAC GAAGCATTAC CGATGACTTC  
ACGCTGACCA

8451 GTCCCTACCT GGGGTCTGCG CCGTATTGCA GACACTCAGC  
20 GCCATGTTTT

8501 AGCCCAATAA AAATTGAGAA CGTGTGGGAC GAATCTGATG  
ATGGGTTCGAT

25 8551 TAGAATCCAG GTCTCGGCAC AATTCGGCTA CAATCAGGCA  
GGCACTGCAG

8601 ACGTCACCAA GTTCCGGTAC ATGTCTTACG ACCACGACCA  
TGACATCAAG

30 8651 GAAGACAGTA TGGAGAAAAT AGCTATTAGT ACATCTGGAC  
CATGCCGTCG

8701 TCTTGGCCAC AAAGGGTACT TCCTGTTAGC TCAATGTCCT  
35 CCAGGTGACA

8751 GTGTAACCGT CAGTATCACG AGCGGAGCAT CTGAGAATTC  
ATGCACCGTG

40 8801 GAGAAAAAGA TCAGGAGGAA GTTTGTCGGT AGAGAGGAGT  
ACTTGTTCCC

8851 ACCTGTCCAT GGAAAGCTGG TAAAGTGCCA CGTTTACGAT  
CACTTGAAGG

45 8901 AGACGTCTGC CGGATACATA ACCATGCACA GGCCAGGCCC  
ACACGCGTAT

8951 AAGTCCTATC TGGAGGAAGC GTCAGGCGAA GTGTACATTA  
50 AACCACCTTC

9001 TGGCAAGAAC GTCACCTACG AATGTAAGTG TGGTGA CTAC  
AGCACAGGTA

5 9051 TTGTGAGCAC GCGAACGAAG ATGAACGGCT GCACTAAAGC  
AAAACAATGC

9101 ATTGCCTACA AGCGCGACCA AACGAAATGG GTCTTCAACT  
CGCCGGATCT

10 9151 TATTAGGCAC ACAGACCACT CAGTGCAAGG TAAACTGCAC  
ATTCCATTCC

9201 GCTTGACACC GACAGTCTGC CCGGTTCCGT TAGCTCACAC  
GCCTACAGTC

15 9251 ACGAAGTGGT TCAAAGGCAT CACCCTCCAC CTGACTGCAA  
CGCGACCAAC

9301 ATTGCTGACA ACGAGAAAAT TGGGGCTGCG AGCAGACGCA  
20 ACAGCAGAAT

9351 GGATTACAGG GACTACATCC AGGAATTTTT CTGTGGGGCG  
AGAAGGGCTG

25 9401 GAGTACGTAT GGGGCAACCA TGAACCAGTC AGAGTCTGGG  
CCCAGGAGTC

9451 GGCACCAGGC GACCCACATG GATGGCCGCA TGAGATCATC  
ATCCACTATT

30 9501 ATCATCGGCA TCCAGTCTAC ACTGTCATTG TGCTGTGTGG  
TGTCGCTCTT

9551 GCTATCCTGG TAGGCACTGC ATCGTCAGCA GCTTGTATCG  
35 CCAAAGCAAG

9601 AAGAGACTGC CTGACGCCAT ACGCGCTTGC ACCGAACGCA  
ACGGTACCCA

40 9651 CAGCATTAGC AGTTTTGTGC TGTATTCTGGC CAACCAACGC  
TGAAACATTT

9701 GGAGAAACTT TGAACCATCT GTGGTTTAAC AACCAACCGT  
TTCTCTGGGC

45 9751 ACAGTTGTGC ATCCCTCTGG CAGCGCTTGT TATTCTGTTC  
CGCTGCTTTT

9801 CATGCTGCAT GCCTTTTTTA TTGGTTGCAG GCGTCTGCCT  
50 GGGGAAGGTA

9851 GACGCCTTCG AACATGCGAC CACTGTGCCA AATGTTCCGG  
GGATCCCGTA

5 9901 TAAGGCGTTG GTCGAACGTG CAGGTTACGC GCCACTTAAT  
CTGGAGATTA

9951 CGGTCGTCTC ATCGGAATTA ACACCCTCAA CTAACAAGGA  
GTACGTGACC

10 10001 TGCAAATTTT ACACAGTCGT TCCTTCACCA CAAGTTAAAT  
GCTGCGGGTC

10051 CCTCGAGTGT AAGGCATCCT CAAAAGCGGA TTACACATGC  
CGCGTTTTTG

15 10101 GCGGTGTGTA CCCTTTCATG TGGGGAGGCG CACAGTGCTT  
CTGTGACAGT

10151 GAGAACACAC AACTGAGTGA GGCATACGTC GAGTTCGCTC  
20 CAGACTGCAC

10201 TATAGATCAT GCAGTCGCAC TAAAAGTTCA CACAGCTGCT  
CTGAAAGTCG

25 10251 GCCTGCGTAT AGTATACGGC AATACCACAG CGCGCCTGGA  
TACATTTCGTC

10301 AACGGCGTCA CACCAGGTTC CTCACGGGAC CTGAAGGTCA  
TAGCAGGGCC

30 10351 GATATCAGCA GCTTTTTTCAC CCTTTGACCA TAAGGTCGTC  
ATTAGAAAGG

10401 GGCTTGTTTA CAACTACGAC TTCCCTGAGT ATGGAGCTAT  
35 GAACCCAGGA

10451 GCGTTCGGCG ATATTCAAGC ATCCTCTCTT GATGCCACAG  
ACATAGTAGC

40 10501 CCGCACCGAC ATACGGCTGC TGAAGCCTTC TGTCAAGAAC  
ATCCACGTCC

10551 CCTACACCCA AGCAGTATCA GGGTATGAAA TGTGGAAGAA  
CAACTCAGGA

45 10601 CGACCCCTGC AAGAAACAGC ACCATTCGGA TGTAATAATTG  
AAGTGGAGCC

10651 TCTGCGAGCG ACTAACTGTG CTTATGGGCA CATCCCTATC  
50 TCGATTGACA

10701 TCCCTGATGC AGCTTTTGTG AGATCATCTG AATCACCAAC  
AATTTTAGAA

5 10751 GTCAGCTGCA CAGTAGCAGA CTGCATTTAT TCTGCAGACT  
TTGGTGGTTC

10801 GCTAACACTA CAGTACAAAG CTAACAGAGA GGGACATTGT  
CCAGTTCACT

10 10851 CCCACTCCAC TACAGCTGTT TTGAAGGAAG CGACCACACA  
TGTGACTGCC

10901 ACAGCCATAA CACTACATTT TAGCACATCG AGCCCACAAG  
CAAATTTTCAT

15 10951 AGTTTCGCTA TGGCGCAAGA AGACCACCTG CAATGCTGAA  
TGTAACCAC

11001 CGGCCGACCA CATAATTGGA GAACCACATA AGGTGACCA  
20 AGAATTCCAG

11051 GCGGCAGTTT CCAAAACATC TTGGAAGTGG CTGCTTGCAC  
TGTTTGGGGG

25 11101 AGCATCATCC CTCATTGTTG TAGGACTTAT AGTGTTGGTC  
TGCAGCTCTA

11151 TGCTTATAAA CACACGTAGA TGACTGAGCG CGGACACTGA  
CATAGCGGTA

30 11201 AAAACTCGAT GTACTTCCGA GGAAGCGTGG TGCATAATGC  
CACGCGCCGC

11251 TTGACACTAA AACTCGATGT ATTTCCGAGG AAGCACAGTG  
35 CATAATGCTG

11301 TGCAGTGTC AATTAATCGT ATATTACACT ACATATTAAC  
AACACTATAT

40 11351 CACTTTTATG AGACTCACTA TGGGTTTCTA ATACACACTA  
CACACATTTT

11401 ATTTAAAAAC ACTACACACA CTTTATAAAT TCTTTTATAA  
TTTTTCTTTT

45 11451 GTTTTTTATT TTGTTTTTAA AATTTCAAAA AAAAAAAAAA  
AA

## (3) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:  
5 (A) LENGTH: 11464 base pairs  
(B) TYPE: Nucleic acid  
(C) STRANDEDNESS: Double  
(D) TOPOLOGY: Unknown  
1 ATGGGCGGCG CATGAGAGAA GCCCAAACCA ATAAC TACCC  
10 AAAATGGAGA AAGTTCACGT  
61 TGACATCGAG GAAGATAGTC CCTTCCTCAG AGCATTACAA  
CGGAGCTTCC CGCAGTTTGA  
121 GGTAGAAGCC AAGCAGGTCA CAGATAATGA CCATGCTAAC  
GCCAGAGCGT TTTCGCATTT  
15 181 GGCATCGAAA TTGATCGAGA CGGAGGTGGA ACCATCCGAT  
ACGATCCTAG ACATTGGAAG  
241 TGCGCCTGCC CGCAGAATGT ATTCCAAGCA TAAGTACCAT  
TGCATCTGTC CGATGAAATG  
301 TGCAGAAGAT CCGGACAGAC TGTTTAAGTA TGCAGCCAAG  
20 CTGAAGAAGA ACTGTAAAGA  
361 GATTACAGAT AAGGAACTGG ACAAGAAGAT GAAGGAGCTT  
GCGGAAGTCA TGAGCGACCC  
421 TGATCTCGAA ACTGAAACGA TTTGCCTTCA CGACGATGAA  
ACCTGTCTGAT TTGAGGGTCA  
25 481 AGTCGCAGTG TATCAGGATG TGTACGCGGT TGACGGACCG  
ACGAGCCTTT ACCATCAGGC  
541 CAACAAAGGG GTCAGAGTCG CCTATTGGAT AGGATTCGAC  
ACTACCCCTT TTATGTTTAA  
601 GAACCTGGCT GGAGCATATC CCTCCTATTC GACCAACTGG  
30 GCCGACGAGA CCGTGTTAAC  
661 GGCTCGTAAT ATAGGCTTGT GCAGCTCCGA TGTGATGGAG  
CGGTCACGTA GAGGGATGTC  
721 CATCCTCAGA AAGAAATTTT TAAAACCATC CAATAACGTC  
TTGTTCTCTG TAGGATCTAC  
35 781 CATCTACCAC GAGAAGCGAG ACTTACTAAG GAGTTGGCAC  
CTACCGTCCG TTTTTCACCT

841 ACGTGGTAAG CAGAATTACA CTTGTCGGTG TGAGACTATA  
GTTAGTTGCG ACGGGTACGT  
901 CGTCAAAAGG ATAGCTATTA GTCCAGGTCT GTACGGGAAA  
CCGTCGGGCT ACGCTGCCAC  
5 961 GATGCATCGC GAGGGATTCT TGTGCTGCAA GGTGACGGAC  
ACGCTTGACG GGGAGAGGGT  
1021 CTCTTTCCCC GTATGCACGT ACGTGCCAGC CACATTGTGC  
GACCAAATGA CAGGCATTCT  
1081 GGCAACAGAT GTCAGTGCAG ACGACGCGCA GAAATTGCTG  
10 GTTGGGCTCA ACCAGCGAAT  
1141 AGTCGTAAAT GGCCGCACTC AAAGGAATAC TAACACAATG  
AAGAACTATT TATTACCCGT  
1201 CGTGGCACAA GCATTTGCCA GATGGGCTAA AGAGTACACA  
GAAGATCAAG AAGATGAAAG  
15 1261 ACCATTGGGG CTTAGGGACC GCCAGTTGGT AATGGGGTGT  
TGTTGGGCGT TCAGGAAACA  
1321 CAAGATAACA TCAGTGTACA AACGACCAGA CACCCAAACG  
ATCATCAAGG TAAACAGCGA  
1381 TTTCCACTCT TTCGTGCTGC CCAGAATTGG AAGCAACACC  
20 TTGGAGATTG GGCTGAGGAC  
1441 CAGGATCAGA AAATACTGG AGGAACCTGT GGACAGACCA  
CCACTGATTA CCGCCGACGA  
1501 CATAAGGAA GCCAAGAACG CGGCGGATGA GGCTAAGGAA  
GTCAAGGAGG CCGAAGAGCT  
25 1561 CAGGGCAGCA TTACCACCGC TGTCTGCCGA TGTAAGGAA  
CCTGCACTGG AGGCGGACGT  
1621 TGACTTAATG CTGCAGGAGG CGGGAGCAGG ATCTGTCGAA  
ACCCCCAGGG GGCTCATCAA  
1681 AGTCACCAGT TATGCAGGAG AAGACAAAAT TGGCTCTTAT  
30 GCGGTGCTCT CCCCACAAGC  
1741 AGTACTGCGA AGTGAAAAAC TGACGTGCAT CCACCCGCTT  
GCAGAGCAAG TAATTGTAAT  
1801 CACACACTCT GGAAGGAAGG GTAGATACGC AGTTGAGCCT  
TACCACGGAA AAGTGGTAGT

1861 ACCCGAAGGG CAAGCTATAC CTGTCCAAGA CTTCCAAGCA  
CTCAGTGAGA GCGCCACAAT  
1921 TGTGTACAAC GAACGTGAGT TCGTGAATAG GTATTTACAC  
CACATTGCCA CGCACGGTGG  
5 1981 AGCTCTGAAC ACAGACGAGG AGTATTACAG AGTGGTGAAA  
CCTAGTGAAC ATGAAGGTGA  
2041 GTACTTATAT GACATTGACA AGAAACAATG TGTGAAGAAA  
GAACTGGTTA CGGGACTAGG  
2101 TTTGACAGGA GAACTTGTCG ATCCCCCCTT CCATGAATTT  
10 GCATATGAAA GCTTGAGGAC  
2161 ACGTCCGCCC GCACCTTATC AAGTACCAAC TATAGGTGTG  
TATGGCGTTC CCGGGTCCGG  
2221 GAAGTCTGGA ATTATTAAGA GCGCAGTCAC AAAGAAGGAC  
TTGGTAGTGA GTGCTAAGAA  
15 2281 GGAGAACTGC GCCGAGATAA TAAGGGACGT CAAGAAGATG  
AAAGGGCTAG ACGTCAATGC  
2341 CCGGACGGTG GACTCAGTGC TGTAAATGG ATGCAAGCAC  
CCGGTCGAGA CTTTGTACAT  
2401 TGATGAAGCC TTTGCATGCC ACGCCGGCAC TCTCAGGGCC  
20 TTAATAGCCA TTATACGCCC  
2461 AAAGAAAGCA GTGCTATGTG GTGACCCAAA GCAATGTGGC  
TTCTTCAACA TGATGTGCCT  
2521 GAAAGTGCAC TTCAACCATG AAATATGCAC TCAAGTTTTT  
CACAAAAGCA TATCTCGCAG  
25 2581 GTGTACCAAG TCAGTGACGT CGGTAGTGTC CACACTGTTT  
TATGACAAAA GAATGAGAAC  
2641 TACTAACCCA AGGGATTCCA AAATCGAAAT TGACACAACA  
GGAAGTACTA AACCAAAAAA  
2701 GGATGACTTG ATTCTCACAT GTTTTAGGGG ATGGGTAAAG  
30 CAACTGCAAA TAGACTACAA  
2761 AGGAAATGAA ATAATGACCG CGGCTGCCTC ACAGGGATTG  
ACGCGGAAAG GTGTCTATGC  
2821 AGTTAGGTAC AAAGTTAACG AGAACCATT GTACGCACCC  
ACCTCAGAGC ATGTAAATGT



2881 GCTGTTGACC CGGACGGAAG ACAAGATTGT GTGGAAGACT  
CTTGCAGGGG ACCCGTGGAT

2941 AAAGACCCTG ACCGCGAAGT ACCCCGGAGA TTTCAC TGCA  
ACAATGGAAG AATGGCAGGC

5 3001 AGAACATGAT GCCATCATGA GACACATCCT GGAGAAACCG  
GATCCCACGG ATGTCTTCCA

3061 AAATAAAGCT AATGTTTGCT GGGCAAAGGC ACTTG TACCT  
GTGCTTAAGA CAGCCGGGAT

3121 AGATTTGACC ACAGAGCAGT GGAACACAGT GGATTACTTC

10 AAAGAGGATA AGGCCCACTC

3181 AGCTGAGATT GTCCTGAATC AGCTGTGCGT GCGATTCTTC  
GGTCTAGACT TAGATTCTGG

3241 TTTGTTTTCC GCCCCACAG TTCCACTCTC CATTAGGAAC  
AACCATTGGG ACAACTCACC

15 3301 GTCACCCAAC ATGTACGGGT TGAATCAAGA AGTGGTCAGG  
CAACTATCAC GCAGGTACCC

3361 TCAATTACCA CGTGCGGTGA CTACTGGGAG AGCATACGAC  
ATGAACACCG GTACTTTGCG

3421 CAATTATGAT CCGCGCATAA ATTTAGTACC GGTGAACCGT

20 CGTCTACCAC ATGCTCTCGT

3481 GACGCAACAT GCTGATCATC CTCCCAGTGA TTTTCCGCC  
TTTGTCAGTA AGCTTAAAGG

3541 CAGAACGGTC CTAGTAGTTG GTGAGAAGAT GAGTATTTCA  
GGTAAGACGG TAGACTGGTT

25 3601 ATCTGAAACA CCTGATTCTA CTTT TAGGGC GCGCCTAGAT  
CTAGGCATAC CCAATGAACT

3661 ACCGAAGTAC GATATCGTCT TCGTAAATGT AAGAACACAG  
TACCGCTACC ACCACTACCA

3721 GCAGTGTGAG GACCACGCCA TTAAGTTGAG CATGTTGACC

30 AAGAAGGCCT GCCTGCACCT

3781 GAACCCCGGA GGAACCTGTG TGAGCATTGG TTACGGCTAT  
GCGGACCGGG CCAGTGAAAG

3841 CATCATAGGT GCAGTTGCTC GGCAGTTCAA GTTCTCGAGG  
GTATGCAAAC CGAAGGTGTC

3901 TAAGGAGGAG ACCGAAGTGC TATTTGTCTT CATTTGGGTTC  
GATCGTAAAA CGCGAACCCA  
3961 TAACCCATAC AAGCTCTCCT CCACCCTGAC CAATATTTAC  
ACCGGCTCGA GGCTCCATGA  
5 4021 AGCTGGCTGC GCACCTTCGT ATCATGTAGT GCGCGGGGAT  
ATAGCCACTG CCACGGAAGG  
4081 AGTAATCGTT AATGCTGCCA ACAGCAAGGG CCAGCCAGGC  
AGTGGAGTGT GCGGAGCTCT  
4141 GTACCGGAAG TACCCCGAAA GCTTCGATTT ACAACCAATA  
10 GAAGTGGGGA AAGCTAGATT  
4201 GGTCAAAGGT AACTCAAAC ATCTCATTCA TGCAGTGGGG  
CCGAATTTTA ACAAAGTGTC  
4261 TGAAGTGGAA GGTGACAAAC AGCTGGCAGA AGCGTATGAA  
TCTATAGCCA GGATTATTAA  
15 4321 TGACAACAAT TATAGATCTG TGGCTATTCC GCTTCTGTCC  
ACTGGAATAT TTGCCGAAA  
4381 CAAGGATAGG TTAATGCAAT CCTTAAACCA TCTGTAAACG  
GCATTGGACA CAACAGACGC  
4441 AGATGTGGCC ATATACTGCA GAGACAAGAA ATGGGAAGTG  
20 ACGTTGAAAG AGGTCGTAGC  
4501 CAGGAGAGAG GCGGTAGAGG AGATATGTAT CTCCGAAGAT  
TCCTCCGTAG CAGAGCCGGA  
4561 TGCAGAGCTG GTTAGAGTTC ACCCTAAGAG CTCTTTGGCT  
GGAAGGAAAG GTTACAGCAC  
25 4621 TAGCGATGGG AAGACATTCT CATATCTTGA AGGAACCAA  
TTTCATCAGG CGGCGAAGGA  
4681 CATGGCAGAA ATTAACGCTA TGTGGCCTGC CGCTACAGAG  
GCTAATGAGC AGGTGTGCTT  
4741 ATACATTCTG GGTGAAAGTA TGAGCAGTAT AAGATCCAAA  
30 TGCCCCGTTG AGGAGTCAGA  
4801 GGCATCCACC CCACCAAGTA CATTGCCTTG CTTGTGCATC  
CACGCTATGA CCCCAGAACG  
4861 GGTTCAGCGT TTGAAAGCCT CCCGCCCCGA ACAAATTACA  
GTTTGTCTT CCTTCCATT

4921 GCCGAAGTAC AGAATAACAG GAGTGCAGAA GATTCAATGT  
TCGCATCCTA TACTTTTCTC

4981 TCCTAAAGTA CCTGAGTACA TACACCCTAG AAAGTACCTT  
GCAGACGCAG CTTCGCAAA

5 5041 CAATGGGGCA GCCGAATCAA CATCGGTGGA CGTGCAGCCA  
CAGCTGGAAG AGAGTCCTGA

5101 GAACACGGAA CAACTGGTGG AGGAGGAAGA CAGTATAAGC  
GTGCTGTCTG AGGATACACC

5161 ACACCAAGTG CACCAAGTGG AGGCTGAAGT GCATCGCTTC  
10 AGCGCAAGTG CTCAATCTTC

5221 GTCCTGGTCC ATTCCACGTG CATCCGACTT TGATGTCGAG  
AGTCTTTCCG TGCTCGAATC

5281 CCTGGGTGCT AATGATACAA TCAGCATGGA GTCGTCCTCA  
AACGAAACAG CTCTTGCTTT

15 5341 GCGGACCATT TTTAAGACTC CACCCATTCC AAGGCCTCGA  
GTGCAGAGCA CATCCACAGA

5401 CGTGGTTAGT ATCTCAGCAC TCGAGTCTTG TGACAGCACC  
AGCGATGCGC GTAGCATAGA

5461 CTCGGATGAA ACCGATGTTT CCATCTTTGA CAAAAGGTTG  
20 GAGTTCCTGG CCAGACCTGT

5521 TCCCGCACCG CGAACCAAAT TTAGGACTCC ACCCGTCCCG  
AAACCGCGTG CGCGGAGGCC

5581 ATTACATCCT TTGTCTAGTA GATCAAGCTC GCGCTCTAGC  
CTGGCGTCTA ATCCACCAGG

25 5641 TGTTAACCGA GTGATCACTA GGAAGAATT TGAGTCCTTC  
GTTGCCCAAC AGCAATGACG

5701 GTTCGACGCG GGCGCGTACA TTTTCTCCTC GGATACTGGT  
CAAGGACATT TGCAACAAAA

5761 ATCAGTAAGG CAGACAGTAT TGTCTGAAGT GGTGCTAGAG  
30 AGGACTGAGT TAGAGATCTC

5821 GTACGCCCCG CGCCTCGACC TGAACAAAGA AGAAATACTG  
AGAAAGAAGT TACAAC TGAA

5881 CCCTACGCAA GCTAACCGGA GTAGATATCA GTCACGGAGG  
GTTGAAAACA TGAAGGCCAT

5941 AACAACTAAG AGAATCTTAC AGGGATTAGG TCACTACCTG  
AAATCTGAAG GCAAGGTGGA  
6001 GTGCTATCGT ACGTTGCACC CCGTACCTTT GTATTCAGCA  
AGTGTGAACA GAGCGTTCTC  
5 6061 CAGTCCCAA GTTGCTGTTG AAGCATGTAA CGTTGTTCTG  
AAGGAAAATT TTCCGACAGT  
6121 GCGTCGTAC TGCATAATAC CTGAGTACGA CGCCTACTTG  
GACATGGTGG GCGGTGCATC  
6181 ATGTTGCTTG GATACGGCGA GTTTTGTCCC TGCCAAGTTG  
10 CGTAGCTTTC CGAAGAAACA  
6241 CGCATACCTC GAGCCCACCA TTCGGTCTGC AGTCCCATCA  
GCAATTCAGA ACACGCTGCA  
6301 AAATGTACTC GCAGCTGCCA CAAAGAGAAA CTGCAATGTG  
ACTCAAATGA GGGAGCTGCC  
15 6361 TGTACTGGAT TCTGCGGCCT TCAATGTAGA GTGTTTAA  
AAATACGCTT GCAATAATGA  
6421 GTATTGGGAG ACCTACAAGA AGAATCCTAT TAGATTGACC  
GAGGAAAATG TGGTCAACTA  
6481 TATAACCAAG TTAAAAGGGC CGAAGGCGGC TGCCCTGTAT  
20 GCAAAGACTC ATAATTTAGA  
6541 CATGCTGCAA GACATACCCA TGGACAGGTT TATTATGGAT  
TTAAAAGAG ATGTCAAGGT  
6601 AACTCCAGGA ACCAAGCATA CCGAAGAAAG GCCTAAGGTC  
CAAGTAATCC AGGCTGCAGA  
25 6661 TCCATTGGCT ACAGCATACC TATGTGGGAT TCATAGAGAA  
TTGGTGCGCA GACTGAACGC  
6721 AGTTCTGTTG CCAACATAC ACACATTATT TGACATGTCT  
GCTGAGGATT TCGACGCCAT  
6781 AATTGCCGAG CACTTCCAAC CAGGCGATTG GGTGTTAGAG  
30 ACAGACATAG CGTCATTCGA  
6841 TAAAAGCGAA GATGACGCGA TGGCTCTGAC GGCCTGATG  
ATCCTGGAAG ACCTCGGGGT  
6901 GGACCCAGAG CTGTTGACCC TAATCGAAGC GGCATTTGGC  
GAAATATCCT CCATTCACTT

6961 ACCAACCAAA ACTAAATTTA GGTTTGGAGC CATGATGAAA  
TCAGGGATGT TCTTGACTCT  
7021 GTTTGTCAAT ACTGTGATCA ATATGGTCAT AGCTAGCAGA  
GTTCTGCGTG AGAGACTGAC  
5 7081 AAACCTCCCCT TGCGCCGCGT TCATTGGCGA CGACAATATC  
GTGAAAGGGG TTAAGTCCGA  
7141 CAAACTCATG GCCGATAGGT GCGCTACATG GTTGAACATG  
GAAGTCAAAA TCATCGACGC  
7201 AGTGGTTGGC GAGAAAGCTC CCTACTTCTG TGGTGGGTTT  
10 ATTTTATGTG ACTCTGTGAC  
7261 CGGAACTGCA TGCCGTGTAG CAGACCCTTT GAAGAGATTA  
TTTAAGCTTG GAAAACCACT  
7321 GGCTGTGGAT GATGAACATG ATGATGACAG GCGTCGAGCA  
CTACAGGAGG AATCTGCCCCG  
15 7381 GTGGAACCGG GTGGGAATTT TTTCCGAGCT GTGCAAAGCC  
GTCGAGTCGC GATATGAAAC  
7441 AGTGGGCACG GCTGTCATTA TCATGGCCAT GACTACGCTC  
GCCAGCAGTG TCGAGTCGTT  
7501 CAGTTGTCTA AGAGGGGCTT CTATATCCCT CTACGGCTAA  
20 CCTGAATGGA CTGCGACGTA  
7561 GTCAAGTCCG CCGAAATGTT TCCTTATCAA CCAATGTACC  
CAATGCAGCC CATGCCCTTC  
7621 CGCAACCCTT TTGCGACTCC CAGAAGACCA TGGTTTCCAA  
GGACCGACCC CTTTTTAGCG  
25 7681 ATGCAGGTGC AAGAGCTGGC AAGGTCCATG GCCAACTTGA  
CGTTCAAGCA ACGGCGAGAT  
7741 GTGCCGCCCC AGGGTCCACC GGCTAAGAAG AAGAAGAAGG  
ACAACTCGCA ACAAGGTGGT  
7801 CGGAATCAGA ATGGAAAGAA AAAGAACAAG CTAGTAAAGA  
30 AAAAGAAGAA GACAGGGCCA  
7861 CCACCCCCAA AAAATACTGG TGGCAAAAAG AAAGTCAATA  
GGAAGCCAGG GAAGAGACAA  
7921 CGAATGGTTA TGAAGTTGGA GTCAGACAAG ACATTCCCTA  
TCATGCTAGA TGGAAAAGTT

7981 AATGGATATG CATGCGTGGT CGGTGGCAAG CTGTTTAGAC  
CACTGCATGT GGAGGGTAAG  
8041 ATTGACAATG ACGTGTGTGTC CTCCCTCAAG ACCAAAAAGG  
CATCTAAGTA TGATCTGGAG  
5 8101 TATGCTGATG TGCCGCAGAG CATGCGCGCA GACACATTTA  
AATACACTCA TGAAAAACCC  
8161 CAGGGCTATT ACAGCTGGCA CCATGGAGCA GTACAGTATG  
AAAATGGCAG ATTCACAGTG  
8221 CCCAAAGGAG TCGGAGCCAA AGGAGATAGC GGTGCCCCCA  
10 TACTTGACAA CCAAGGGCGT  
8281 GTGGTCGCTA TTGTGCTTGG CGGAGTGAAT GAAGGCTCCA  
GAACGGCACT GTCTGTCGTG  
8341 ACGTGGAACG AAAAAGGGGT TACAGTCAAA TACACCCCCG  
AGAATAGCGA GCAGTGGTCC  
15 8401 CTGGTGACCA CCATGTGCCT GCTAGCCAAT GTCACGTTCC  
CGTGCACCCA ACCACCCATC  
8461 TGCTACGACC GTAAGCCAGC AGAGACTTTG TCCATGCTCA  
GTCATAACAT AGACAATCCT  
8521 GGTTATGACG AGTTGCTCGA AGCAGTACTG AAATGTCCAG  
20 GCAGAGGCAA GAGGTCCACG  
8581 GAGGAGCTGT TTAAGGAGTA CAAGTTAACA CGCCCGTACA  
TGGCCAGGTG CATCAGGTGT  
8641 GCGGTCGGAA GTTGCCACAG CCCCATAGCC ATAGAGGCGG  
TAAGGAGCGA AGGGCACGAT  
25 8701 GGCTATGTAC GACTCCAGAC CTCATCTCAG TATGGATTAG  
ACCCATCAGG AACTTGAAA  
8761 GGCAGAACCA TGAGGTATGA TATGCATGGA ACCATAGAAG  
AGATACCGTT GCATCAGGTG  
8821 TCTGTTTATA CCTCACGTCC TTGCCACATA ATAGATGGGC  
30 ATGGATACTT TCTGCTTGCC  
8881 AGGTGCCCTG CAGGAGACTC CATAACTATG GAATTTAAGA  
AAGAATCAGT CACCCATTCC  
8941 TGCTCTGTGC CCTACGAAGT AAAGTTTAAT CCTGCGGGAA  
GAGAACTGTA CACACACCCA

9001 CCAGAGCACG GAGCTGAACA ACCTTGTCAC GTGTACGCTC  
ACGACGCACA AAATAGGGGA  
9061 GCTTACGTGG AAATGCACCT TCCAGGATCC GAAGTGGACA  
GTACTTTACT GTCCATGAGC  
5 9121 GGTA GTTCTG TTCATGTGAC TCCACCTGCC GGGCAAAGCG  
TCCAAGTGGA ATGCGAATGT  
9181 GGTGGCACCA AGATCTCTGA AACCATCAAT TCAGCTAAAC  
AATACAGTCA GTGCTCAAAG  
9241 ACATCTCAGT GCAGGGCATA CCGTACACAG AATGACAAAT  
10 GGGTGTACAA TTCGGATAAA  
9301 CTGCCTAAAG CATCGGGAGA AACTCTCAA GGCAAATTGC  
ATGTGCCCTT CGTACTGACC  
9361 GAAGCGAAAT GCACAGTACC ATTGGCTCCA GAACCCATTA  
TCACCTTTGG GTTCCGCTCT  
15 9421 GTGTCTCTGA AACTTCATCC TAAGAACCCC ACCTTCCTAA  
CCACGAGGCA GCTGGATGGA  
9481 GAACCAGCTT ACACCCACGA ACTTATAACC CACCCTGTGG  
TGAGAAATTT CTCGGTTACA  
9541 GAGAAAGGTT GGAATTTGT GTGGGGAAAC CATCCGCCTC  
20 AAAGGTACTG GTCTCAAGAA  
9601 ACTGCACCAG GTAATCCACA CGGACTACCA CACGAGGTGA  
TCACGCATTA CTATCACAGA  
9661 TATCCCATGT CCACCATCCT CGGCTTATCA ATCTGTGCGG  
CGATAGTGAC GACATCCATT  
25 9721 GCGGCATCCG TATGGCTGTT TTGCAAATCA CGGATTTTCAT  
GCCTGACCCC CTATCGCTTG  
9781 ACTCCGAATG CCAGCATGCC TCTGTGCTTA GCCGTCTTGT  
GCTGCGCACG CACAGCCAAA  
9841 GCCGAACTA CTTGGGAATC CCTAGATCAC CTCTGGAACC  
30 ACAACCAGCA GATGTTCTGG  
9901 AGTCAGCTGC TAATCCCGCT AGCAGCACTG ATAGTTGCTA  
CCCCTTGCT GAAATGTGTG  
9961 TGTTGCGTTG TGCCTTTTTT AGTCGTGGCC GGCGCCGTAG  
GCGCCGGCGC TTACGAGCAC

10021 GCGACTACGA TGCCGAACCA AGTGGGGATC CCGTATAATA  
CCATTGTCAA CAGAGCGGGT

10081 TATGCACCTC TACCTATTAG CATAGTACCT ACTAAAGTGA  
AGCTGATTCC AACAGTGAAT

5 10141 CTTGAGTACA TTACATGCCA TTACAAGACT GGAATGGATT  
CACCCGCCAT TAAATGCTGC

10201 GGCACCTCAGG AGTGTCTCTCC AACTTACAGG CCGGACGAGC  
AATGCAAAGT CTTCTCTGGA

10261 GTATACCCAT TTATGTGGGG AGGGGCGTAT TGCTTTTGCG  
10 ATACGGAGAA TACCCAGATA

10321 AGCAAGGCGT ACGTGACGAA ATCGGAAGAT TGCCTCACCG  
ATCACGCCCCA GGCATACAAA

10381 GCACATACAG CCTCAGTCCA AGCCTTCTTA AATATTACAG  
TTGGAGGACA CTCAACGACA

15 10441 GCAGTGGTGT ATGTGAATGG AGAGACTCCC GTTAATTTTA  
ATGGAGTGAA GCTGACCGCG

10501 GGCCCTCTGT CCACAGCCTG GTCGCCGTTC GACAAGAAGA  
TCGTGCAGTA CGCCGGGGAA

10561 ATTTATAACT ATGACTTTCC GGAATATGGA GCCGGCCACG  
20 CAGGAGCGTT TGGTGACATC

10621 CAGGCTAGGA CGGTATCTAG TTCCGATGTA TACGCCAACA  
CAAACCTTGT GCTGCAGAGA

10681 CCCAAAGCCG GAGCGATCCA TGTCCCGTAC ACCCAGGCCC  
CATCTGGGTA TGAACAATGG

25 10741 AAGAAAGATA AACCACCATC CCTCAAGTTC ACAGCCCCGT  
TCGGTTGTGA AATTACACC

10801 AACCCTATCC GTGCTGAAAA CTGCGCTGTG GGATCAATTC  
CGCTAGCTTT TGACATTCCC

10861 GATGCTCTGT TTACCAGGGT GTCCGAAACA CCGACATTAT  
30 CTGCTGCCGA GTGCACTCTG

10921 AACGAGTGTG TATATTCATC CGACTTTGGC GGGATCGCTA  
CAGTCAAATA CTCGGCGAGC

10981 AAGTCAGGCA AATGTGCAGT TCATGTACCC TCAGGCACGG  
CTACATTGAA AGAAGCCGCA



11041 GTCGAGTTGG CCGAACAGGG TTCGGCTACT ATACATTTTT  
CGACTGCCAG CATTCATCCG  
11101 GAGTTTACAG TCCAGATATG CACGTCTTAC GTTACGTGCA  
AAGGGGATTG TCACCCTCCG  
5 11161 AAAGATCACA TTGTGACGCA TCCCCAATAC CACGCCAGT  
CATTTACAGC TGCGGTATCA  
11221 AAAACCGCTT GGACGTGGTT AACATCCTTA CTGGGAGGGT  
CAGCTATAAT TATAATAATT  
11281 GGAATTGTGT TAGCCACAGT TGTGGCTATG TATGTGCTGA  
10 CCAACCAGAA ACATAATTAG  
11341 TATTAGCAGC GATTGGCATG CTGCTTGTAAG AGTTTTATTA  
CAAATAACGT GCGGCAATTG  
11401 GCGAGCCGCT TTAATTAGAA TTTTATTTTC TTTTACCATA  
ATTGGATTTT GTTTTAAATA  
15 11461 TTTC

(4) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
20 (A) LENGTH: 4003 base pairs  
(B) TYPE: Nucleic acid  
(C) STRANDEDNESS: Double  
(D) TOPOLOGY: Unknown

25 Nucleotide Sequence of the BeAn8 26S Subgenomic  
cDNA containing last portion of NS4, the 26S promoter,  
the complete BeAn8 structural genes and a portion of  
the 3' noncoding region.

30 1 CCCAGTAACT CTCTACGGCT GACCTGAATG GACTGTAACG  
TAGTTCAGTC  
51 CGCAACCATG TTCCCTTACC AATCACCAAT GTTTCCAATG  
35 CAACCAGCGC  
101 CTTTTCGCAA CCCGTACGCT CCTCCTAGAA GACCGTGGTT  
CCCTAGAACC  
40 151 GATCCCTTCT TAGCCATGCA GGTGCAGGAG TTGGCCCGAT  
CAATGGCGAG  
201 CTTGACGTTT AAACAGCGTC GAGATACGCC ACCCGAGGGG  
CCACCTGCTA

251 AGAAGAAGCG TAAGGAGCCT CAACAGCAGG TAGCTCAGGC  
GCAGGTTAAG

5 301 AAAAAGAACG GAAAACCGAA GAAGAAGAAA AGTAACGGAG  
CACCACCCCC

351 AAAAAATCAG AAGAGCACCA AGAAGAAGAC CAATAAGAAA  
CCTGGAAAAA

10 401 GACAACGGAT GGTTATGAAG TTAGAATCAG ACAAACATT  
TCCTATTTTG

451 CTGGATGGAA AAATTAATGG ATATGCTTGC GTTGTTGGAG  
15 GAAAGCTATT

501 TCGACCCATG CACGTGGAAG GCAAATTTGA CAATGAAACT  
CTTGCCTCCC

20 551 TGAAGACGAA GAAGGCATCC AAATACGACC TAGAGTATGC  
CGATGTTCTT

601 CAAAGCATGC GAGCAGATAC CTTTAAATAC ACACATGATA  
AGCCTCAAGG

25 651 GTATTATAAT TGGCATCACG GCGCCGTGCA GTATGAAAAT  
GGGAGATTCA

701 CGGTGCCGAA AGGTGTGGGA GCGAAAGGAG ACAGTGGACG  
30 CCCCATACTA

751 GATAATCAAG GCAGAGTCGT GGCCATTGTG CTGGGAGGGG  
TGAATGAAGG

35 801 ATCCAAGACA GCTTTGTCCG TAGTTATGTG GAATGAAAAA  
GGGGTCACCG

851 TAAAATATAC ACCAGAAAAC TGTGAGCAAT GGTCAC TAGT  
40 TACCACCATG

901 TGTCTTCTCG CCGATGTTAC GTTCCCTTGT TCCACTCCAC  
CAATTTGCTA

951 CGACCGAGCA CCCGCAGAAA CCCTGATGAT GCTTAGCAAG  
45 AACATTGACA

1001 ATCCTGGCTA TGATGAATTG CTGGAAGCAG TGCTGAAATG  
CCCCGGCAGA

50 1051 CAGAAGAGAT CTACGGAGGA GTTATTTAAG GAGTACAAAC  
TTACACGTCC

1101 GTACATGGCC AAGTGTGTGC GGTGTGCCGT TGGAAGTTGC  
CACAGCCCCGA

1151 TCGCTATAGA AGCAGTAAGA AGCGACGGGC ATGACGGCTA  
5 CATCCGAATA

1201 CAGACATCAT CACAGTACGG TTTAGACCCC TCCGGGAACG  
TTAAGAGCAG

1251 AGTTATGAGG TATAATCTGT ATGGCAAGAT CGTAGAAGTT  
10 CCATTACATC

1301 AGGTTTCATT ACACACATCT CGGCCTTGCC ACATTATTGA  
TGGTCACGGA  
15

1351 TATTTCTCC TCGCACGCTG CCCAGAGGGC GACTCTATCA  
CCATGGAGTT

1401 TAAGAAGGAT TCCGTCACCC ATTCCTGTTC AGTGCCTTAT  
20 GAAGTGAAAT

1451 TCACACCCGT GGGCAGAGAA TTATATAGCC ATCCCCCAGA  
ACACGGCACA

1501 GAACATCCGT GCCGTGTGTA TGCCACGAC GCCCAGCAAA  
AAGATGCGTA  
25

1551 TGTGGAGATG CACCTGCCCCG GGTCCGAAGT TGACAGTTCC  
CTGCTCTCCA  
30

1601 TGAGCGGTAG TGCGGTCCGG GTAACACCAC CATCAGGGCA  
AAGTGTCTTT

1651 GTGGAGTGCA ACTGTGGCTC CGCTGTGTCTG GAAACCATAA  
35 AACTGCAAA

1701 ATCATAACAGC CAATGCACAA AAACATCACA ATGCCGCGCG  
TACCGTCTGC

1751 AGAATGATAA GTGGGTATAC AATTCAGACA AACTTCCAAA  
GGCATCGGGA  
40

1801 GAAACGCTGA AAGGGAACT GCATGTACCT TATCTCCTTT  
CCGAAGCGAA  
45

1851 GTGTACCGTA CCTTTAGCAC CCGAGCCAAT AGTAACCTTC  
GGCTTTTCGAT

1901 TCGTATCTTT GAAATTGCAT CCACGGAATC CGACATATTT  
50 GACTACCCGC

1951 CAGCTAGATG GAGAACCGAA TTACACCCAC GAGCTAATTT  
CAGAGCCAAC

5 2001 AACTAGAAAT TTTACAGTGA CTGAGCATGG ATGGGGATAC  
GTTTGGGGTA

2051 ATCACCCGCC TCAGAGGTAC TGGGCACAGG AGACAGCTCC  
AGGCAACCCG

10 2101 CATGGGCTGC CGCACGAGGT GATTACTCAT TACTATAACA  
GGTACCCAAT

2151 GTCCACGATT TTCGGACTAT CGATTTGCGC CGCAGTGGTA  
ACCACCTCAA

15 2201 TAGCCGCATC CACCTGGCTG TTGTGCAAGT CGAGAGTATC  
TTGTTTGAAT

2251 CCGTATCGAC TGACCCCGAA TGCTCAGTTA CCTGTGTGTC  
20 TAGCCTTCCT

2301 GTGCTGCGCG AGGACAGCCC GTGCAGAGAC CACATGGGAA  
TCACTAGACC

25 2351 ATTTATGGAA CCATAATCAA CAGATGTTCT GGAGTCAACT  
GCTCATTCCC

2401 CTAGCCGCGC TCATTGTGGT GACCCGCTTG CTGAAGTGCA  
TGTGTTGCGT

30 2451 CGTTCCTTTT TTAGTCCTAG CAGGCGCCGC AAGCGTCGGC  
GCCTACGAAC

2501 ACGCAACCAC GATGCCGAAT CAGGTGGGGA TCCCGTATAA  
35 TACAGTAGTC

2551 AACC GCGCAG GTGACGCACC ATTGGCAATC AGCATTATTC  
CAACCAAGAT

40 2601 ACGGCTAATT CCTACTTTGA ATTTAGAATA TATTACATGC  
CACTATAAGA

2651 CAGGATTAGA TTCACCTTTC ATTAAATGCT GCGGAACGCA  
GGAATGCCCC

45 2701 CAAGTGAATA GACCCGATGA ACAGTGTAAG GTCTTCACGG  
GGGTGTATCC

2751 GTTTATGTGG GGAGGCGCCT ACTGCTTCTG TGAATCTGAA  
50 AACACGCAAA

2801 TTAGTCGAGC GTATGTGATG AAATCAGATG ACTGCTCAGC  
TGACCACGCC

2851 TTGGCCTACA AAGCTCATAC TGCCTCAGTC CAAGCTTTTC  
5 TGAATATAAC

2901 TGTGGGAGAG CAATCGACGA CAGCGGTAGT GTACGTGAAT  
GGAGAAACAC

2951 CGGTCAATTT TAACGGCATT AAATTGGTTG CAGGCCCTTT  
10 ATCAACTGCC

3001 TGGACCCCAT TTGATCGGAA AGTGGTGCAG TACGCCGGAG  
AGATCTACAA  
15

3051 TTATGACTTC CCGGAGTACG GAGCTGGGCA TGCAGGGGCG  
TTCGGGGATC

3101 TTCAAGCCAG AACAAATCACC AGTAATGACC TGTACGCCAA  
20 CACGAATTTA

3151 GTATTGCAAA GACCCAACAC AGGCACCATC CATGTTTCCTT  
ACACGCAGGC

3201 ACCGTCAGGC TTTGAGCAGT GGAAGAAAGA CAAACCACCA  
25 TCATTAAAGT

3251 ACACCGCACC ATTTGGGTGC GAAATTCATG TGAATCCCGT  
CAGAGCTGAG  
30

3301 AATTGCGCAG TAGGATTTAT ACCATTAGCC TTCGACATAC  
CCGATGCCTT

3351 GTTTACCAGG GTGTCAGAAA CACCGACGTT GTCGAGCGCT  
35 GAGTGCTCCT

3401 TGAATGAGTG TACATACTCA ACGGACTTTG GCGGGATCGC  
CACTGTCAAG

3451 TACTCGGCTA GTAAATCAGG CAAATGCGCA GTACATGTTC  
40 CCTCAGGCAC

3501 TGCAACTCTG AAAGAGTCAT TGGTGGAAGT GGTCGAACAA  
GGGTCAATGA  
45

3551 CCCTTCACTT TTCGACCGCC AGTATACACC CAGAGTTTAA  
ATTGCAGATC

3601 TGTACGAAGG TACTCACATG TAAAGGCGAC TGTCATCCGC  
50 CTAAAGACCA

3651 TATTGTGACG CACCCCCAGC ACCACGCCCA GACATTTACA \*  
GCTGCGGTAT

3701 CCAAGACCGC TTGGACGTGG TTAACGTCAC TCTTAGGAGG  
5 GTCAGCAGTA

3751 ATTATTATAA TTGGCCTTGT ATTAGCAACT GTTGTTGCTA  
TGTATGTGCT

3801 GACCAACCAG AAACATAATT AGACCACAGC AGCGATTGGA  
10 AAGCTGCCTA

3851 TTAGAAACAT GTAGCGGCAA TTGGCAAGCC GCCTATAAAT  
GTTTAGCAGC  
15

3901 AATTGGCAAG CTGCATATAT AAATTACCTA GCGGCAATTG  
GCACGCCGCT

3951 TATAAAATTT TTATTTTCTT TTACCAATAA TTGGATTTTG  
20 TTTTAAATAT

4001 TTC

25

30

35

40

What is claimed is:

1. A DNA comprising an isolated and purified western equine encephalitis (WEE) virus cDNA fragment  
5 coding for infectious western equine Encephalitis virus genome.

2. A DNA according to claim 1 wherein said WEE cDNA fragment is operably linked to a promoter  
10 such that said cDNA is transcribed.

3. The DNA according to claim 1, wherein said cDNA fragment contains a deletion in the E3-E2 cleavage site.  
15

4. The DNA according to claim 3, wherein said cDNA fragment deletion is 5 amino acids at the E2-E2 cleavage site said amino acids being Arg Arg Pro Lys Arg.  
20

5. The DNA according to claim 4 wherein said cDNA fragment further contains a suppressor mutation.

6. The DNA according to claim 5 wherein said  
25 suppressor mutation is a substitution of glutamic acid at codon 182 of E2 to lysine.

7. The DNA according to claim 5 wherein said suppressor mutation is a substitution of glutamic acid  
30 at codon 181 of E2 to lysine.

8. The DNA according to claim 2 wherein said promoter is T7 promoter of pBluescript KS and said DNA is pWE2000.

9. An infectious WEE virus RNA transcript encoded by the cDNA fragment of claim 1.

5           10. A DNA according to claim 5 wherein said WEE cDNA fragment is operably linked to a promoter such that said cDNA is transcribed.

10           11. An attenuated WEE virus RNA transcript encoded by the cDNA fragment of claim 5.

15           12. A DNA according to claim 6 wherein said WEE cDNA fragment is operably linked to a promoter such that said cDNA is transcribed.

15           13. An attenuated WEE virus RNA transcript encoded by the cDNA fragment of claim 6.

20           14. A DNA according to claim 7 wherein said WEE cDNA fragment is operably linked to a promoter such that said cDNA is transcribed.

25           15. An attenuated WEE virus RNA transcript encoded by the cDNA fragment of claim 7.

25           16. Infectious WEE virus particles containing an RNA transcript according to claim 9.

30           17. Attenuated WEE virus particles containing an RNA transcript according to claim 11.

            18. Attenuated WEE virus particles containing an RNA transcript according to claim 13.



19. Attenuated WEE virus particles  
containing an RNA transcript according to claim 15.

20. A live attenuated western equine  
5 encephalitis (WEE) virus vaccine comprising attenuated  
western equine encephalitis virus according to claim  
17.

21. A live attenuated western equine  
10 encephalitis (WEE) virus vaccine comprising attenuated  
Western Equine Encephalitis virus according to claim  
18.

22. A live attenuated western equine  
15 encephalitis (WEE) virus vaccine comprising attenuated  
western equine encephalitis virus according to claim  
19.

23. A DNA comprising an isolated and  
20 purified venezuelan equine encephalitis virus IE  
variant (VEE IE) cDNA fragment coding for infectious  
venezuelan equine encephalitis virus IE variant virus  
genome.

25 24. A DNA according to claim 23, wherein  
said cDNA fragment has the sequence of SEQ ID NO:2 or  
a portion thereof, or an allelic portion thereof.

25. The DNA according to claim 23, wherein  
30 said cDNA fragment contains a deletion in the E3-E2  
cleavage site.

26. A DNA according to claim 25, wherein  
said cDNA fragment contains a deletion according to

claim 25 wherein said deletion is four amino acids  
said amino acids being Arg Gly Lys Arg.

27. A DNA fragment according to claim 26  
5 wherein said VEE IE cDNA further contains a suppressor  
mutation.

28. A DNA according to claim 23 wherein said  
VEE IE cDNA fragment is operably linked to a promoter  
10 such that said cDNA is transcribed.

29. An infectious VEE IE virus RNA  
transcript encoded by the cDNA fragment of claim 23.

30. A DNA according to claim 27 wherein said  
15 VEE IE cDNA fragment is operably linked to a promoter  
such that said cDNA is transcribed.

31. An attenuated VEE IE virus RNA  
20 transcript encoded by the cDNA fragment of claim 27.

32. Infectious VEE IE virus particles  
containing an RNA transcript according to claim 29.

33. Attenuated VEE IE virus particles  
25 containing an RNA transcript according to claim 31.

34. A live attenuated venezuelan equine  
encephalitis virus IE variant (VEE IE) virus vaccine  
30 comprising attenuated venezuelan equine encephalitis  
virus IE variant virus according to claim 33.

35. A bivalent alphavirus vaccine comprising  
live attenuated western equine encephalitis (WEE)  
35 virus comprising an attenuating mutation and live

attenuated venezuelan equine encephalitis virus IE variant (VEE IE) comprising an attenuating mutation.

36. A bivalent alphavirus vaccine according to claim 35 wherein said live attenuated western equine encephalitis virus is chosen from the group consisting of attenuated WEE comprising a deletion in the E3-E2 cleavage site and a substitution of glutamic acid at codon 182 of E2 to lysine, and attenuated WEE comprising a deletion in the E3-E2 cleavage site and a substitution of glutamic acid at codon 181 of E2 to lysine.

37. An attenuated western equine encephalitis virus wherein said virus comprises an attenuating mutation selected from the group consisting of: a C to T change at nucleotide 7 of the 5' noncoding region of the WEE genome, a A to G change at nucleotide 13 of the 5' noncoding region of the WEE genome, a T to A change at nucleotide 25 of the 5' noncoding region of the WEE genome, and a deletion of an A at nucleotide 22 of the 5' noncoding region of the WEE genome.

38. A pharmaceutical formulation comprising attenuated WEE virus particles according to claim 17 in an effective immunogenic amount in a pharmaceutically acceptable carrier.

39. A pharmaceutical formulation comprising attenuated WEE virus particles according to claim 18 in an effective immunogenic amount in a pharmaceutically acceptable carrier.

40. A pharmaceutical formulation comprising attenuated WEE virus particles according to claim 19 in an effective immunogenic amount in a pharmaceutically acceptable carrier.

5

41. A pharmaceutical formulation comprising attenuated VEE IE virus particles according to claim 33 in an effective immunogenic amount in a pharmaceutically acceptable carrier

10

42. An attenuated chimeric virus comprising nonstructural sequences from a first alphavirus and structural sequences from a second alphavirus resulting in attenuation of the second alphavirus.

15

43. An attenuated chimeric virus according to claim 42 wherein said first alphavirus is western equine encephalitis virus and said second alphavirus is chosen from the group consisting of: Sindbis virus, Aura virus, Barmah Forest virus, Bebaru Cabassou virus, Chikungunya virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzylogach virus, Mayaro virus, Middelburg virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Ross River virus, Sagiyama virus, Semliki Forest virus, SAAR87 virus, Tonate virus, Una virus, venezuelan equine encephalitis virus, and Whataroa virus.

20  
25  
30

44. An attenuated second virus according to claim 43 wherein said second alphavirus is eastern equine encephalitis virus.

45. An attenuated chimeric second virus according to claim 42 wherein said first alphavirus is

35

Venezuelan equine encephalitis virus variant IE and said second alphavirus is chosen from the group consisting of: venezuelan equine encephalitis virus, western equine encephalitis virus, eastern equine encephalitis virus, Sindbis virus, Aura virus, Barmah Forest virus, Bebaru Cabassou virus, Chikungunya virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzytagach virus, Mayaro virus, Middelburg virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Ross River virus, Sagiyama virus, Semliki Forest virus, SAAR87 virus, Tonate virus, Una virus and Whataroa virus.

46. An attenuated chimeric second virus according to claim 44 wherein said second virus is venezuelan equine encephalitis virus variant IA.

47. An attenuated chimeric second virus according to claim 42 wherein said first alphavirus is venezuelan equine encephalitis virus variant IA and said second alphavirus is chosen from the group consisting of: Venezuelan equine encephalitis virus, western equine encephalitis virus, eastern equine encephalitis virus, Sindbis virus, Aura virus, Barmah Forest virus, Bebaru Cabassou virus, Chikungunya virus, Everglades virus, Fort Morgan virus, Getah virus, Highlands J virus, Kyzytagach virus, Mayaro virus, Middelburg virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Pixuna virus, Ross River virus, Sagiyama virus, Semliki Forest virus, SAAR87 virus, Tonate virus, Una virus, and Whataroa virus.

48. An attenuated chimeric second virus according to claim 47 wherein said second virus is venezuelan equine encephalitis virus variant IE.

49. An attenuated chimeric second virus according to claim 47 wherein said second virus is Venezuelan Equine Encephalitis virus variant IIIA.

5

50. An attenuated virus vaccine comprising chimeric virus according to claim 42 wherein said vaccine is directed against said second alphavirus.

10

51. An inactivated western equine encephalitis virus (WEE) vaccine comprising attenuated WEE according to claim 17 wherein said attenuated WEE is inactivated.

15

52. An inactivated western equine encephalitis virus (WEE) vaccine comprising attenuated WEE according to claim 18 wherein said attenuated WEE is inactivated.

20

53. An inactivated western equine encephalitis virus (WEE) vaccine comprising attenuated WEE according to claim 19 wherein said attenuated WEE is further inactivated.

25

54. An inactivated venezuelan equine encephalitis virus variant IE (VEE IE) vaccine comprising attenuated VEE IE according to claim 33 wherein said attenuated VEE IE is further inactivated.

30

55. An inactivated eastern equine encephalitis virus (EEE) vaccine comprising attenuated EEE according to claim 44 wherein said attenuated virus is further inactivated.

56. An inactivated venezuelan equine encephalitis virus variant IA (VEE/IA) vaccine comprising attenuated VEE/IA according to claim 46 wherein said attenuated virus is further inactivated.

5

57. An inactivated venezuelan equine encephalitis virus variant IIIA (VEE/IA) vaccine comprising attenuated VEE IIIA according to claim 49 wherein said attenuated virus is further inactivated.

10

58. An inactivated venezuelan equine encephalitis virus variant IE (VEE IE) vaccine comprising attenuated VEE IE according to claim 48 wherein said attenuated virus is further inactivated.

15

59. A method for expressing a protein said method comprising cloning a gene encoding said protein into a an attenuated virus replicon, said replicon chosen from the group consisting essentially of attenuated WEE and attenuated VEE IE wherein transcription of said replicon yields RNA capable of infecting a cell in which said protein is to be expressed.

20

60. A method for the diagnosis of western equine encephalitis virus (WEE) infection comprising the steps of :

25

(i) contacting a sample from an individual suspected of having a WEE infection with all or a unique portion of WEE; and

30

(ii) detecting the presence or absence of a WEE infection by detecting the presence or absence of a complex formed between WEE and antibodies specific therefor in the sample.

61. A method for the diagnosis of venezuelan equine encephalitis virus variant IE (VEE IE) infection comprising the steps of :

- 5           (i) contacting a sample from an individual suspected of having a VEE IE infection with all or a unique portion of VEE IE; and
- (ii) detecting the presence or absence of a VEE IE infection by detecting the presence or absence
- 10       of a complex formed between VEE IE and antibodies specific therefor in the sample.

62. A method for the diagnosis of western equine encephalitis virus (WEE) from a sample using

15       the polymerase chain reaction, said method comprising:

- (i) extracting RNA from the sample;
- (ii) reverse transcribing the RNA of (i) to DNA;
- (iii) contacting said DNA with
- (a) at least four nucleotide triphosphates,
- 20           (b) a primer that hybridizes to WEE DNA, and
- (c) an enzyme with polynucleotide synthetic activity,

          under conditions suitable for the hybridization and extension of said first primer by said enzyme,

25       whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed;

          (iv) denaturing said duplex to release said first DNA product from said DNA;

30       (v) contacting said first DNA product with a reaction mixture comprising:

- (a) at least four nucleotide triphosphates,
- (b) a second primer that hybridizes to said first DNA, and



(c) an enzyme with polynucleotide synthetic activity,

under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed;

(vi) denaturing said second DNA product from said first DNA product;

(vii) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;

(viii) fractionating said first and second DNA products generated from said WEE DNA; and

(ix) detecting said fractionated products for the presence or absence of WEE in a sample.

63. A method for the diagnosis of venezuelan equine encephalitis variant IE virus (VEE IE) from a sample using the polymerase chain reaction, said method comprising:

(i) extracting RNA from the sample;  
(ii) reverse transcribing said RNA of (i) to DNA;  
(iii) contacting said DNA with  
(a) at least four nucleotide triphosphates,  
(b) a primer that hybridizes to VEE IE DNA,  
and

(c) an enzyme with polynucleotide synthetic activity,

under conditions suitable for the hybridization and extension of said first primer by said enzyme, whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed;

(iv) denaturing said duplex to release said first DNA product from said DNA;

(v) contacting said first DNA product with a reaction mixture comprising:

- 5                   (a) at least four nucleotide triphosphates,  
                  (b) a second primer that hybridizes to said first DNA, and  
                  (c) an enzyme with polynucleotide synthetic activity,

10           under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed;

15           (vi) denaturing said second DNA product from said first DNA product;

                  (vii) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;

20           (viii) fractionating said first and second DNA products generated from said VEE IE DNA; and

                  (ix) detecting said fractionated products for the presence or absence of VEE IE in a sample.

25                   64. A method for providing protective immunity against a second alphavirus to individuals with pre-existing immunity to a first alphavirus said method comprising administering to said individuals an effective amount of live attenuated second alphavirus.

30                   65. A method for providing protective immunity against a second alphavirus according to claim 64, wherein said live attenuated second alphavirus is attenuated western equine encephalitis virus.

35

66. The method of claim 65 wherein said western equine encephalitis (WEE) virus is chosen from the group consisting of: attenuated WEE having a  
5 substitution of glutamic acid at codon 181 of E2 to lysine, attenuated WEE having a substitution of glutamic acid at codon 181 of E2 to lysine, attenuated WEE having a C to T change at nucleotide 7  
of the 5' noncoding region of the WEE genome,  
10 attenuated WEE having a A to G change at nucleotide 13 of the 5' noncoding region of the WEE genome, attenuated WEE having a T to A change at nucleotide 25 of the 5' noncoding region of the WEE genome, and  
attenuated WEE having a deletion of an A at nucleotide  
15 22 of the 5' noncoding region of the WEE genome.

67. A method for providing protective immunity against a second alphavirus according to claim 64, wherein said live attenuated second  
20 alphavirus is attenuated venezuelan equine encephalitis virus variant IE.

68. A WEE infection diagnostic kit comprising primers specific for WEE and ancillary  
25 reagents suitable for use in detecting the presence or absence of WEE in a mammalian sample.

69. A VEE IE infection diagnostic kit comprising primers specific for VEE IE and ancillary  
30 reagents suitable for use in detecting the presence or absence of VEE IE in a mammalian sample.

70. An isolated and purified Venezuelan equine encephalitis variant IIIA cDNA encoding the VEE  
35 IIIA structural genes.

71. An amino acid fragment encoded by the cDNA fragment according to claim 70.

5           72. A polypeptide encoded by the amino acid fragment according to claim 71.

10

15

20

25

30

35

## Assembly module WE3'-17 1 / 7




FIGURE 1A

## Assembly c noc 3 pWE5'-18 2 / 7




FIGURE 1B

Assembly of pWE2000 full length cDNA clone of western  
equine encephalitis virus from modules pWES'-18 and  
pWE3'-17




FIGURE 1C



FIGURE 2







FIGURE 3

**Figure 4**





## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10645

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12N 15/40, 7/01, 7/04, 15/86; A61K 39/193.

US CL : 536/23.72; 435/235.1, 236, 69.1, 172.3; 424/205.1, 218.1

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.72; 435/235.1, 236, 69.1, 172.3; 424/205.1, 218.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Aps, Biosis, Cab, Derwent WPI. Search terms: western, equine(w)enceph?, attenuat?, venezuelan, genom?, ma. clon?, sequenc?, dna, dnas, "E2", "E3", wee.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FRAIZER, G. et al. Isolation and preliminary characterization of mutants of Western equine encephalomyelitis virus with altered virulence in chickens. Biological Abstracts. 1985. Vol. 80, No. 5, page AB-506, Abstract no. 41179, see entire abstract.	16
Y	US 5,185,440 A (DAVIS et al) 09 February 1993, see entire document, particularly column 7, line 66 through column 8, line 1.	1-3, 8, 9, 16, 59
Y	US 5,505,947 A (JOHNSTON et al) 09 April 1996, see particularly column 3, lines 50-54, Abstract, and Examples 1 and 2.	3, 59

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

"	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

27 AUGUST 1998

Date of mailing of the international search report

06 OCT 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARY E. MOSHER, PH.D.

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/10645

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WEAVER, S.C. et al. A comparison of the Nucleotide Sequences of Eastern and Western Equine Encephalomyelitis Viruses with Those of Other Alphaviruses and Related RNA Viruses. Virology. 1993. Vol. 197, pages 375-390. See figures 3 and 4.	1-3, 8, 9, 16, 59
Y	HAHN, C.S. et al. Western equine encephalitis virus is a recombinant virus. Proceedings of the National Academy of Sciences USA. August 1988. Vol. 85, p. 5997-6001. See Figure 1.	1-3, 8, 9, 16, 59
A	STRAUSS, J.H. et al. The Alphaviruses: Gene Expression, Replication, and Evolution. Microbiological Reviews. September 1994. Vol. 58, No. 3, pages 491-562.	1-22, 37-40, 51-53, 59

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/10645

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-22, 37-40, 51-53, 59

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10645

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group 1, claims 1-22, 37-40, 51-53, 59, drawn to a first product DNA encoding an infectious genome of Western Equine Encephalitis (WEE) virus, RNA and virus encoded by DNA, vaccines and pharmaceuticals comprising virus encoded, and methods of use.

Group 2, claims 23-34, 41, 54, 59 drawn to second product DNA encoding an infectious genome of Venezuelan Equine Encephalitis IE variant (VEE IE) virus, RNA and virus encoded by DNA, vaccines and pharmaceuticals comprising virus encoded, and methods of use.

Group 3, claims 35-36, drawn to third product, combination vaccine comprising attenuated WEE and attenuated VEE IE

Group 4, claims 42-50, 55-58, drawn to fourth product, chimeric alphavirus and vaccine.

Group 5, claims 62, 68, drawn to fifth product, WEE specific primer kit, and method of use.

Group 6, claims 63, 69, drawn to sixth product, VEE IE specific primer kit, and method of use

Group 7, claims 70-72, drawn to seventh product, DNA encoding structural genes of VEE variant IIIA and products encoded.

Group 8, claims 60, drawn to method of diagnosing WEE using antigen.

Group 9, claims 61, drawn to method of diagnosing VEE IE using antigen.

Group 10, claims 64-67, drawn to method of vaccinating immune individual using a second alphavirus.

The inventions listed as Groups 1-10 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

In groups 1 and 2, the special technical feature in each case is the DNA encoding an infectious genome of a particular virus; since groups 1 and 2 pertain to two distinct viruses, they involve different special technical features.

Group 3 does not have the corresponding special technical feature, because the attenuated viruses required in group 3 are not limited to those made by using the DNAs of groups 1 or 2; for example claim 35 encompasses combination vaccines using viruses attenuated by propagation in culture.

Group 4 does not have the corresponding special technical feature, because it is not limited to either of the viruses encoded by the DNAs of group 1 or group 2; for example claim 42 encompasses a chimera made from Sindbis and Semliki Forest viruses.

Groups 5 and 6 do not have the corresponding special technical feature, because they require small, specific primers, not infectious full-length genomic materials.

Group 7 does not have the corresponding special technical feature, because is drawn to a sub-genomic fragment of a third virus.

Groups 8 and 9 do not have the corresponding special technical feature, because they are not limited to materials of groups 1 or 2; for example claim 60 encompasses a method using viral antigens produced by propagation of native WEE in standard tissue culture.

Group 10 does not have the corresponding special technical feature because it is not limited to the viruses made using the DNAs of groups 1 or 2; for example claim 64 encompasses a method of vaccinating a Sindbis-immune monkey

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/10645

against Semliki Forest virus.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**